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A B S T R A C T
Background
Ear discharge (otorrhoea) is common in children with grommets (ventilation/tympanostomy tubes); the proportion of children devel-
oping discharge ranges from 25% to 75%. The most common treatment strategies include oral broad-spectrum antibiotics, antibiotic
eardrops or those containing a combination of antibiotic(s) and a corticosteroid, and initial observation. Important drivers for one
strategy over the other are concerns over the side effects of oral antibiotics and the potential ototoxicity of antibiotic eardrops.
Objectives
To assess the benefits and harms of current treatment strategies for children with ear discharge occurring at least two weeks following
grommet (ventilation tube) insertion.
Search methods
The Cochrane ENT Information Specialist searched the ENT Trials Register, CENTRAL (2016, Issue 5), multiple databases and
additional sources for published and unpublished trials (search date 23 June 2016).
Selection criteria
Randomised controlled trials comparing at least two of the following: oral antibiotics, oral corticosteroids, antibiotic eardrops (with or
without corticosteroid), corticosteroid eardrops, microsuction cleaning of the ear canal, saline rinsing of the ear canal, placebo or no
treatment. The main comparison of interest was antibiotic eardrops (with or without corticosteroid) versus oral antibiotics.
Data collection and analysis
Weused the standardmethodological procedures expected by Cochrane. Primary outcomes were: proportion of children with resolution
of ear discharge at short-term follow-up (less than two weeks), adverse events and serious complications. Secondary outcomes were:
proportion of children with resolution of ear discharge at intermediate- (two to four weeks) and long-term (four to 12 weeks) follow-up,
proportion of children with resolution of ear pain and fever at short-term follow-up, duration of ear discharge, proportion of children
with chronic ear discharge, ear discharge recurrences, tube blockage, tube extrusion, health-related quality of life and hearing. We used
GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.
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Main results
We included nine studies, evaluating a range of treatments, with 2132 children who developed acute ear discharge beyond the immediate
postoperative period. We judged the risk of bias to be low to moderate in most studies.
Antibiotic eardrops (with or without corticosteroid) versus oral antibiotics
Antibiotic eardrops with or without corticosteroid were more effective than oral antibiotics in terms of:
- resolution of discharge at one week (one study, 42 children, ciprofloxacin eardrops versus amoxicillin: 77% versus 30%; risk ratio
(RR) 2.58, 95% confidence interval (CI) 1.27 to 5.22; moderate-quality evidence);
- resolution of discharge at two weeks (one study, 153 children, bacitracin-colistin-hydrocortisone eardrops versus amoxicillin-clavu-
lanate: 95% versus 56%; RR 1.70, 95% CI 1.38 to 2.08; moderate-quality evidence);
- duration of discharge (two studies, 233 children, ciprofloxacin eardrops versus amoxicillin: median 4 days versus 7 days and bacitracin-
colistin-hydrocortisone eardrops versus amoxicillin-clavulanate: 4 days versus 5 days; moderate-quality evidence);
- ear discharge recurrences (one study, 148 children, bacitracin-colistin-hydrocortisone eardrops versus amoxicillin-clavulanate: 0 versus
1 episode at six months; low-quality evidence); and
- disease-specific quality of life (one study, 153 children, bacitracin-colistin-hydrocortisone eardrops versus amoxicillin-clavulanate:
difference in change in median Otitis Media-6 total score (range 6 to 42) at two weeks: -2; low-quality evidence).
We found no evidence that antibiotic eardrops were more effective in terms of the proportion of children developing chronic ear
discharge or tube blockage, generic quality of life or hearing.
Adverse events occurred at similar rates in children treated with antibiotic eardrops and those treated with oral antibiotics, while no
serious complications occurred in either of the groups.
Other comparisons
(a) Antibiotic eardrops with or without corticosteroid were more effective thancorticosteroid eardrops in terms of:
- duration of ear discharge (one study, 331 children, ciprofloxacin versus ciprofloxacin-fluocinolone acetonide versus fluocinolone
acetonide eardrops: median 5 days versus 7 days versus 22 days; moderate-quality evidence).
(b) Antibiotic eardrops were more effective than saline rinsing of the ear canal in terms of:
- resolution of ear discharge at one week (one study, 48 children, ciprofloxacin eardrops versus saline rinsing: 77% versus 46%; RR
1.67, 95% CI 1.04 to 2.69; moderate-quality evidence);
but not in terms of tube blockage. Since the lower limit of the 95% CI for the effect size for resolution of ear discharge at one week
approaches unity, a trivial or clinically irrelevant difference cannot be excluded.
(c) Eardrops containing two antibiotics and a corticosteroid (bacitracin-colistin-hydrocortisone) were more effective than no treatment in
terms of:
- resolution of discharge at two weeks (one study; 151 children: 95% versus 45%; RR 2.09, 95% CI 1.62 to 2.69; moderate-quality
evidence);
- duration of discharge (one study; 147 children, median 4 days versus 12 days; moderate-quality evidence);
- chronic discharge (one study; 147 children; RR 0.08, 95% CI 0.01 to 0.62; low-quality evidence); and
- disease-specific quality of life (one study, 153 children, difference in change in median Otitis Media-6 total score (range 6 to 42)
between groups at two weeks: -1.5; low-quality evidence).
We found no evidence that antibiotic eardrops were more effective in terms of ear discharge recurrences or generic quality of life.
(d) Eardrops containing a combination of an antibiotic and a corticosteroid were more effective than eardrops containing antibiotics (low-
quality evidence) in terms of:
- resolution of ear discharge at short-term follow-up (two studies, 590 children: 35% versus 20%; RR 1.76, 95% CI 1.33 to 2.31); and
- duration of discharge (three studies, 813 children);
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but not in terms of resolution of discharge at intermediate-term follow-up or proportion of children with tube blockage. However,
there is a substantial risk of publication bias, therefore these findings should be interpreted with caution.
Authors’ conclusions
We found moderate to low-quality evidence that antibiotic eardrops (with or without corticosteroid) are more effective than oral
antibiotics, corticosteroid eardrops and no treatment in children with ear discharge occurring at least two weeks following grommet
insertion. There is some limited, inconclusive evidence that antibiotic eardrops aremore effective than saline rinsing. There is uncertainty
whether antibiotic-corticosteroid eardrops are more effective than eardrops containing antibiotics only.
P L A I N L A N G U A G E S U M M A R Y
Interventions for children with ear discharge occurring at least two weeks following grommet placement
Review question
This review compares the effects and safety of interventions in children with grommets who develop ear discharge beyond the immediate
postoperative period.
Background
The insertion of grommets (1 to 2 mm plastic tubes placed into the eardrum) is one of the commonest surgical procedures performed
in children worldwide. Up to three in four children with grommets develop episodes of ear discharge. When this occurs beyond the
immediate postoperative period, it is thought to be a symptom of a middle ear infection. The most common treatments include oral
antibiotics (i.e. by mouth), antibiotic eardrops or those containing a combination of antibiotic(s) and a corticosteroid, and initial
observation. Important reasons for physicians to choose one treatment over another are concerns over the side effects of oral antibiotics
and the potential risk of damage to the inner ear and hearing loss due to the use of antibiotic eardrops.
Study characteristics
This review includes evidence up to 23 June 2016. We included nine studies with a total of 2132 children who developed acute ear
discharge beyond the immediate postoperative period. The studies evaluated a range of treatments.
Key results
We primarily looked at the difference in the proportion of children whose ear discharge had resolved within two weeks after treatment
was started, adverse events and serious complications. Secondary outcomes were the proportion of childrenwhose discharge had resolved
at two to four weeks and four to 12 weeks, the proportion of children whose ear pain and fever had resolved within two weeks, the
duration of discharge, the proportion of children with chronic discharge, discharge recurrences, tube blockage, tube extrusion, health-
related quality of life and hearing.
Antibiotic eardrops (with or without corticosteroid) versus oral antibiotics
Antibiotic eardrops with or without corticosteroid were more effective than oral antibiotics in terms of resolution of ear discharge at
one week (moderate-quality evidence) and two weeks (moderate-quality evidence), ear discharge recurrences (low-quality evidence) and
disease-specific quality of life (low-quality evidence). We found no evidence that antibiotic eardrops were more effective in reducing the
risk of chronic ear discharge (low-quality evidence), tube blockage (low-quality evidence), general quality of life (low-quality evidence)
or hearing (very low-quality evidence). Adverse events occurred at similar rates (low-quality evidence), while no serious complications
occurred in either of the groups (very low-quality evidence).
Other comparisons
Antibiotic eardrops with or without corticosteroid were more effective than corticosteroid eardrops in terms of duration of ear discharge
(moderate-quality evidence).
Antibiotic eardropswere more effective than saline rinsing in terms of resolution of ear discharge at one week (moderate-quality evidence),
but not in terms of tube blockage (low-quality evidence). Also, we cannot exclude an unimportant difference between antibiotic eardrops
and saline rinsing in terms of resolution of discharge at one week.
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Eardrops containing two antibiotics and a corticosteroid were more effective than no treatment in terms of resolution of ear discharge at
two weeks (moderate-quality evidence), duration of ear discharge (moderate-quality evidence), reducing the risk of chronic ear discharge
(low-quality evidence) and disease-specific quality of life (low-quality evidence).We found no evidence that antibiotic eardrops were more
effective in terms of ear discharge recurrences (low-quality evidence) or general quality of life (low-quality evidence).
Low-quality evidence suggests that antibiotic and corticosteroid combination eardrops are more effective than eardrops containing antibiotics
only in terms of resolution of ear discharge within two weeks and duration of ear discharge, but not in terms of resolution of ear discharge
at two to four weeks or tube blockage. There is a substantial risk of publication bias, therefore these findings should be interpreted with
caution.
Quality of evidence and conclusion
We found moderate to low-quality evidence that antibiotic eardrops (with or without corticosteroid) are more effective than oral
antibiotics, corticosteroid eardrops and no treatment in children with ear discharge occurring at least two weeks following grommet
placement. There is some limited, inconclusive evidence that antibiotic eardrops are more effective than saline rinsing. There is
uncertainty whether antibiotic-corticosteroid eardrops are more effective than eardrops containing antibiotics only.
4Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics for children with grommets (ventilation tubes) who develop ear discharge beyond the immediate
postoperative period
Patients: children with grommets who develop ear discharge beyond the immediate postoperat ive period
Setting: primary and secondary care
Intervention: ant ibiot ic eardrops (with or without a cort icosteroid)
Control: oral ant ibiot ics
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with oral antibi-
otics
Risk with antibiotic
eardrops
Resolution of ear dis-
charge at short- term
follow-up
(1 week)
Study populat ion RR 2.58
(1.27 to 5.22)
42
(1 RCT)
⊕⊕⊕©
moderate 1
The NNTB based on the
study populat ion risk
was 1/ (774-381)* 1000
= 2.55
300 per 1000 774 per 1000
(381 to 1000)
Adverse events Study populat ion RR 0.37
(0.12 to 1.09)
705
(3 RCTs)
⊕⊕©©
low 2
-
317 per 1000 117 per 1000
(38 to 345)
Serious complications Study populat ion n/ a 153
(1 RCT)
⊕©©©
very low 3
-
0 per 1000 0 per 1000
(0 to 0)
Resolution of ear dis-
charge at intermedi-
ate- term follow-up
(2 weeks)
Study populat ion RR 1.70
(1.38 to 2.08)
153
(1 RCT)
⊕⊕⊕©
moderate 4
-
558 per 1000 949 per 1000
(771 to 1000)
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Duration of ear dis-
charge
Antibiot ic eardrops versus oral ant ibiot ics:
Median 4 days (range 1 to 28) versus 5 days
(range 1 to 36)
Median 4 days (range not reported) versus 7 days
(range not reported)
n/ a 232
(2 RCTs)
⊕⊕⊕©
moderate 4
-
Tube blockage Study populat ion RR 1.20
(0.33 to 4.45)
121
(2 RCTs)
⊕⊕©©
low 5
-
50 per 1000 60 per 1000
(17 to 223)
Health- related quality
of life
Generic - CHQ At 2 weeks, the change in CHQ scores did not dif -
fer signif icant ly between the groups. The change
in Otit is Media-6 total score (range 6 to 42) at
2 weeks was small but favoured ant ibiot ic-cort i-
costeroid eardrops (dif f erence in median dif fer-
ence between treatment groups: -2, P < 0.01)
n/ a 153
(1 RCT)
⊕⊕©©
low 6
-
Disease-specific - OM-6
(range 6 to 42)
Change in median
score: +1 (baseline: 15.
5; 2 weeks: 16.5)
Change in median
score: -1 (baseline: 15.
5; 2 weeks: 14.5)
Dif ference in change in
median OM-6 scores: -2
(in favour of ant ibiot ic
eardrops)
153
(1 RCT)
⊕⊕©©
low 6
-
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CHQ: Child Heath Quest ionnaire; CI: conf idence interval; n/ a: not applicable; NNTB: number needed to treat to benef it ; OM -6: Otit is Media-6; RCT: randomised controlled trial;
RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1We downgraded the evidence f rom high to moderate quality due to imprecise ef fect est imate (small sample size).
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2We downgraded the evidence f rom high to low quality due to study lim itat ions (risk of bias) and inconsistency of ef fect
est imates across individual trials.
3We downgraded the evidence f rom high to very low quality due to study lim itat ions (risk of bias) and imprecise ef fect
est imate (small sample size and inf requent occurrence of outcome).
4We downgraded the evidence f rom high to moderate quality due to study lim itat ions (risk of bias).
5We downgraded the evidence f rom high to low quality due to study lim itat ions (risk of bias) and imprecise ef fect est imate
(inf requent occurrence of outcome).
6We downgraded the evidence f rom high to low quality due to study lim itat ions (risk of bias) and imprecise ef fect est imate
(small sample size).
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B A C K G R O U N D
Description of the condition
The insertion of grommets (also known as ventilation tubes or
tympanostomy tubes) is one of the most common surgical pro-
cedures performed in children worldwide, with 25,000 proce-
dures performed in the UK (Position Paper ENT UK 2009), and
700,000 in the USA each year (Cullen 2009). The two main in-
dications for this operation are restoration of hearing in children
with persistent bilateral otitis media with effusion (also called ’glue
ear’) and prevention of further middle ear infections in children
suffering from recurrent acute otitis media.
Ear discharge (also called otorrhoea) is a common sequela in pa-
tients with grommets; it is generally considered to be a symptom
of a middle ear infection whereby inflammatory secretions that
have built up in the middle ear drain through the grommet into
the ear canal. Clinically a distinction is made between ear dis-
charge occurring during the postoperative period (that is, within
two weeks after grommet insertion), where treatment focuses on
prevention (Syed 2013), and ear discharge developing beyond this
period, which is considered a symptom of a new middle ear infec-
tion. Depending on the age range of children studied, their indi-
cation for grommets and the study design, the proportion of chil-
dren developing ear discharge ranges from 25% to 75% (Ah-Tye
2001; Kay 2001; van Dongen 2013). Ear discharge is unpleasant
and can smell bad, while the underlying middle ear infection can
cause general illness, fever and ear pain. Ear discharge persisting
for three days or more has a negative impact on children’s quality
of life (Rosenfeld 2000). Although most episodes of ear discharge
last only days to weeks, some children with grommets develop
chronic ear discharge, which may be associated with considerable
morbidity and hearing loss.
Description of the intervention
Various treatments and combinations of treatments are currently
used in children with grommets who develop ear discharge. Prefer-
ences vary across countries and healthcare settings. Themost com-
mon strategies include oral broad-spectrum antibiotics, antibiotic
eardrops or those containing a combination of antibiotic(s) and
a corticosteroid, and initial observation. Less common treatments
are systemic or ototopical corticosteroids and interventions like
cleaning of the ear canal using microsuction equipment (in an
ENT setting) and saline rinsing of the ear canal (in a primary care
or ENT setting).
Most ENT surgeons prefer ototopical treatment with antibiotic
eardrops (with or without a corticosteroid) (Badalyan 2013). Pae-
diatricians and general practitioners, on the other hand, tend to
prescribe oral antibiotics or advise to wait and see, driven by guid-
ance and concerns over the potential ototoxicity of ototopical an-
tibiotics when used in children with a non-intact eardrum (includ-
ing grommets) (British National Formulary 2014). Aminoglyco-
sides and chloramphenicol are indeed potentially ototoxic; when
applied locally onto the round window they may penetrate into
the inner ear and cause hair cell damage and sensorineural hearing
loss. Whilst this has been documented in animal studies, there is
little evidence to suggest that similar processes occur when humans
with middle ear disease are treated with these drops; middle ear
secretions and thickened mucosa likely protect the round window
and inner ear from the ototoxic effects of the drops (Pappas 2006;
Phillips 2007).
Quinolones are considered non-ototoxic (Pappas 2006) and they
became widely available as eardrops in the 1990s. The recent clin-
ical practice guideline on tympanostomy tubes in children recom-
mends quinolone drops as the first-line treatment in children with
grommets who develop ear discharge (Rosenfeld 2013). In many
countries, such as the UK, however, otic quinolone formulations
are not widely available (in contrast to ophthalmic formulations).
In this review we will assess the effectiveness and safety of current
interventions for children with grommets who develop ear dis-
charge beyond the immediate postoperative period, with a partic-
ular focus on oral versus ototopical antibiotics.
Treatment strategies for (the prevention of ) ear discharge occur-
ring shortly after the insertion of grommets (also called early post-
operative ear discharge) are beyond the scope of this review and
are addressed in a separate Cochrane Review (Syed 2013).
How the intervention might work
Ear discharge in children with grommets is generally a symptom
of an infection of the middle ear. In addition to the most com-
monbacteria causing acute otitismedia, non-typeableHaemophilus
influenzae, Streptococcus pneumoniae andMoraxella catarrhalis,
Staphylococcus aureus and Pseudomonas aeruginosa are common
pathogens in cultures of ear discharge in children with grommets
(van Dongen 2015).
Treatment of this condition with either ototopical or systemic
antibiotics aims to eradicate these bacteria and cure the infection.
Antibiotic eardrops have the advantage over oral antibiotics of be-
ing delivered directly to the site of infection resulting in higher
local concentrations of antibiotics. This approach is therefore less
likely to cause antimicrobial resistance (Weber 2004), and in addi-
tion avoids the side effects of systemic antibiotics, such as gastroin-
testinal symptoms and skin rash. Ototopical treatment, however,
comes with concerns about ototoxicity and may cause local skin
irritation and allergy.
Corticosteroids, either ototopical or systemic, given as an adjunct
to antibiotic treatment may provide additional benefits by inhibit-
ing the inflammatory cascade evoked in the middle ear as a result
of the infection.
Cleaning the ear canal of ear discharge by microsuction or saline
rinsing of the ear canal allows eardrops to reach the tube and enter
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the middle ear.
Since the middle ear infection that causes ear discharge in children
with grommets may be self-limiting and resolve without treatment
over time, initial observation is practised as an alternative strategy,
in particular in primary care.
Why it is important to do this review
Insertion of grommets is one of the most common surgical proce-
dures in children and episodes of ear discharge are very common
in children receiving grommets, occurring in up to 75% (Ah-Tye
2001; Cullen 2009; Kay 2001; van Dongen 2013). Parents gen-
erally have high expectations that this operation will solve their
child’s middle ear problems and are therefore disappointed when
their child develops ear discharge. The treatment children with
grommets receive for this problem varies widely (Badalyan 2013),
due to varying treatment preferences and differences in guidelines.
Whilst the American Academy of Otolaryngology - Head and
Neck Surgery recommends antibiotic eardrops (Rosenfeld 2013),
the UKNational Institute for Health and Care Excellence (NICE)
recommends taking an ear swab for culture and either treating this
condition as an episode of acute otitis media (initial observation
for uncomplicated disease and oral antibiotics for complicated or
persisting disease) or seeking advice from an ENT surgeon (NICE
2015).
In addition there is uncertainty about the additional benefit of
ototopical or oral corticosteroids, whether interventions to clean
the ear canal are beneficial and whether or not initial observation
is an appropriate treatment strategy.
It is therefore important to review the evidence on the current
management options for children with grommets who develop ear
discharge, so that informed decisions can be made.
O B J E C T I V E S
To assess the benefits and harms of current treatment strategies for
children with ear discharge occurring at least two weeks following
grommet (ventilation tube) insertion.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Children (aged below 18 years) with grommets (irrespective of
type) who developed acute ear discharge outside the immediate
postoperative period, that is ear discharge existing for no more
than three weeks prior to randomisation and occurring at least two
weeks following grommet (ventilation tube) insertion.
Types of interventions
We included all trials comparing the benefits and/or harms of at
least two of the following treatments and comparators:
• Oral antibiotics
• Oral corticosteroids
• Antibiotic eardrops
• Antibiotic(s)-corticosteroid eardrops
• Corticosteroid eardrops
• Cleaning the ear canal using microsuction
• Saline rinsing of the ear canal
• Placebo (in the form of eardrops, oral suspension or tablets,
depending on the ’active’ intervention that is studied) or no
treatment
We included all possible comparison pairs in this review, but the
main comparison of interest is:
• oral antibiotics versus antibiotic eardrops (with or without a
corticosteroid).
As such, we analysed the two different types of antibiotic eardrops
(with and without a corticosteroid) together as a comparison
pair, and performed subgroup analysis to test whether the type
of eardrops impacted on the meta-analysis results (see Subgroup
analysis and investigation of heterogeneity). In a separate analy-
sis, we compared the effectiveness of antibiotic-only eardrops to
eardrops containing antibiotic(s) and a corticosteroid (seeHow the
intervention might work and Subgroup analysis and investigation
of heterogeneity).
We included RCTs reporting on combined interventions (e.g. oral
antibiotics plus antibiotic eardrops versus antibiotic eardrops only)
only if they allowed a direct comparison between one of the com-
bined interventions and a control group and if the groups were
not treated differently except for the treatment under study.
Types of outcome measures
We analysed the primary and secondary outcomes listed below
in this review, but they were not used as a basis for including or
excluding studies.
Primary outcomes
• Proportion of children with resolution of ear discharge at
short-term follow-up (less than two weeks).
• Adverse events likely to be related to the study medications
(ototoxicity, gastrointestinal symptoms, skin rash).
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• Serious complications related to middle ear infection,
including acute mastoiditis and intracranial complications.
Secondary outcomes
• Proportion of children with resolution of ear discharge at
intermediate- (two to four weeks) and long-term (four to 12
weeks) follow-up.
• Proportion of children without other signs of a middle ear
infection (ear pain and fever) at short-term follow-up.
• Duration of ear discharge (after randomisation).
• Proportion of children with chronic ear discharge (longer
than four weeks).
• Number of recurrent ear discharge episodes during follow-
up.
• Proportion of children with tube extrusion.
• Proportion of children with tube blockage.
• Health-related quality of life using a validated instrument;
either disease-specific (e.g. Otitis Media-6) or generic (e.g. EQ-
5D; Infant Toddler Quality of Life Questionnaire; Child Heath
Questionnaire).
• Hearing levels as determined by audiometry.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 23 June 2016.
Electronic searches
The Information Specialist searched:
• the ENT Trials Register (searched 23 June 2016);
• the Cochrane Central Register of Controlled Trials
(CENTRAL 2016, Issue 5);
• Ovid MEDLINE (1946 to May Week 3 2016);
◦ Ovid MEDLINE (In-Process & Other Non-Indexed
Citations 24 June 2016);
◦ PubMed (as a top-up to searches in Ovid MEDLINE
23 June 2016);
• Ovid EMBASE (1974 to 2016 week 25);
• Ovid CAB Abstracts (1910 to 2016 week 23);
• EBSCO CINAHL (1982 to 23 June 2016);
• LILACS, lilacs.bvsalud.org (searched 24 June 2016);
• KoreaMed (searched via Google Scholar 24 June 2016);
• IndMed, www.indmed.nic.in (searched 24 June 2016);
• PakMediNet, www.pakmedinet.com (searched 24 June
2016);
• Web of Knowledge, Web of Science (1945 to 23 June
2016);
• CNKI, www.cnki.com.cn (searched via Google Scholar 24
June 2016);
• ClinicalTrials.gov, (searched via the Cochrane Register of
Studies 23 June 2016);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP), www.who.int/ictrp (searched
23 June 2016);
• ISRCTN, www.isrctn.com (searched 24 June 2016);
• Google Scholar, scholar.google.co.uk (searched 24 June
2016);
• Google, www.google.com (searched 24 June 2016).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searchedOvidMEDLINE,TRIP-
database, TheCochrane Library andGoogle to retrieve existing sys-
tematic reviews relevant to this systematic review, so that we could
scan their reference lists for additional trials.
Data collection and analysis
This review is based on a published protocol (Javed 2015). Any
differences between the published protocol and the review have
been listed in theDifferences between protocol and review section.
Selection of studies
Two review authors independently screened the titles and abstracts
found by the searches and scanned the reference lists of relevant
studies and systematic reviews to assess potential relevance for full
review. The same review authors independently reviewed the full
text of potentially relevant studies against the pre-defined inclu-
sion and exclusion criteria. Any disagreements were resolved by
discussion with a third review author.
Data extraction and management
Two review authors independently extracted data from the in-
cluded trials using a standardised data extraction form. We ex-
tracted the following information from each trial:
• Study characteristics: setting, design, method of data
analysis.
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• Participants: study population, number of participants in
each group, patient characteristics including age, gender,
ethnicity, duration of ear discharge prior to enrollment, number
of discharging ears at baseline and main indication for tube
insertion.
• Interventions: type of intervention and comparison used
including dosage, duration and route of administration.
• Outcomes: primary and secondary outcomes recorded,
adverse events including adverse effects likely to be related to the
use of study medications and serious complications of middle ear
infection.
If a study provided more than one data point within the same time
period (e.g. data on the proportion of patients with resolution of
ear discharge at 5 and 10 days of follow-up), we used the data
point with the shortest duration of follow-up. If a study reported
both parental and otoscopic observations, we used the latter as this
is considered the most objective method of diagnosing resolution
or persistence of middle ear infection (ear discharge) in children.
Any disagreements in data extraction were resolved by discussion
with a third review author.
Assessment of risk of bias in included studies
Two review authors independently assessed the methodological
quality of the included trials and any disagreements were resolved
by discussion with a third review author. We performed ’Risk of
bias’ assessment by using the ’Risk of bias’ tool described in Chap-
ter 8 of theCochrane Handbook for Systematic Reviews of Interven-
tions (Handbook 2011). Cochrane has moved away from high/
low-quality trials to high/low/uncertain risk of bias. We therefore
judged the following domains as high, low or unclear risk of bias:
• sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and personnel (performance bias);
• blinding of outcome assessment (detection bias);
• incomplete outcome data (attrition bias);
• selective outcome reporting (reporting bias);
• other sources of bias.
We presented the results of the ’Risk of bias’ assessment in a ’Risk
of bias’ graph and a ’Risk of bias’ summary.
Measures of treatment effect
We expressed dichotomous outcomes as risk ratios (RRs) with ac-
companying 95% confidence intervals (CIs) and calculated the
number needed to treat to benefit (NNTB). We proposed to ex-
press continuous outcome variables either as mean differences
(MDs), if reported on the same scale, or as standardised mean
differences (SMD), if different continuous scales were used, with
accompanying 95% CIs.
Unit of analysis issues
In the case of cluster-randomised trials, we proposed to use anal-
ysis techniques that take into account the effect of clustering, as
described in Chapter 16 of theCochrane Handbook for Systematic
Reviews of Interventions (Handbook 2011).
Dealing with missing data
One trial author contacted the corresponding trial authors of the
included trials to try to obtain additional information in case of
missing data. For continuous outcomes, we calculated missing
statistics, such as standard deviations (SDs), from other available
statistics (e.g. P values) according the methods described in Chap-
ter 7 of theCochrane Handbook for Systematic Reviews of Interven-
tions (Handbook 2011).
Assessment of heterogeneity
We assessed the level of clinical diversity by reviewing the included
trials for potential differences in study populations, interventions
or comparisons used and outcomes measured. We assessed statis-
tical heterogeneity for each outcome with visual inspection of the
forest plots using the Chi² test, with a significance level set at P <
0.10, and the I² statistic, with I² values of 50% or more suggesting
substantial statistical heterogeneity (Handbook 2011).
Where substantial statistical heterogeneity was present, we car-
ried out pre-specified subgroup analyses and conducted sensitiv-
ity analyses based on the risk of bias (see Subgroup analysis and
investigation of heterogeneity; Sensitivity analysis). We based as-
sessments of differences in effect sizes between subgroups on the
Chi² tests for heterogeneity statistics between subgroups. If none
of these analyses completely resolved statistical heterogeneity then
we employed a random-effects (DerSimonian and Laird) model
to provide amore conservative effect estimate.
Assessment of reporting biases
We searched the internet and ClinicalTrials.gov (http://
clinicaltrials.gov) for available study protocols to determine
whether outcomes reported in the included trials were pre-defined
and whether all outcomes listed in the study protocol were re-
ported in the publication. If there were sufficient trials, we pro-
posed to assess reporting bias by using funnel plots.
Data synthesis
We performed available case analyses, so using data for every par-
ticipant for whom the outcome was obtained, according to the
intention-to-treat (ITT) principle (i.e. analysing participants in
the groups to which they were originally allocated).
We proposed to pool data for the interventions that are listed as a
separate category under the Types of interventions heading but we
intended to analyse the two different interventions of antibiotic
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eardrops (with and without a corticosteroid) together as a com-
parison pair in our main comparison of interest (oral antibiotics
versus antibiotic eardrops (with or without a corticosteroid)).
For dichotomous data, we calculated the RR with 95% CI using
the Mantel-Haenszel method with a fixed-effect (I² values < 50%)
or random-effects (DerSimonian and Laird) model. In addition,
we calculated the number needed to treat to benefit (NNTB) or
number needed to treat to harm (NNTH) based on the average
risks of the control groups in the included studies (’study popula-
tion’) (Handbook 2011).
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis for the following cate-
gories if sufficient data were available:
• duration of ear discharge prior to randomisation (four
weeks or less versus more than four weeks);
• number of discharging ears at baseline (unilateral versus
bilateral discharge);
• main indication for tube insertion (recurrent acute otitis
media versus persistent otitis media with effusion);
• type of eardrops (antibiotic-only eardrops versus eardrops
containing antibiotic(s) and a corticosteroid); eardrops
containing antibiotic(s) and a corticosteroid may be more
effective than antibiotic-only eardrops.
Sensitivity analysis
We proposed to perform a sensitivity analysis in which only trials
judged as low risk of bias (based on a low risk in the key domains
affecting bias including allocation concealment and incomplete
outcome data) were included.
GRADE approach and ‘Summary of findings’
We used the GRADE approach to rate the overall quality of evi-
dence for each outcome. Two review authors (RPV and FJ) inde-
pendently rated the quality of evidence as high, moderate, low or
very low. Any disagreements were resolved by discussion. We rated
evidence from RCTs that did not have serious limitations as high
quality. However, the following factors could lead to downgrading
of the quality of evidence to moderate, low or very low:
• study limitations (risk of bias);
• indirectness of evidence (directness of evidence);
• imprecision (precision of results);
• inconsistency (consistency of results);
• publication bias (existence of publication bias).
We included a ’Summary of findings’ table for the main compar-
ison of interest (oral antibiotics versus antibiotic eardrops with
or without a corticosteroid), which contains what we felt to be
the seven most important outcomes: resolution of ear discharge at
short-term follow-up (one week); adverse events; serious compli-
cations; resolution of ear discharge at intermediate-term follow-
up (two weeks); duration of ear discharge; tube blockage; health-
related quality of life.
R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 1548 records. Removing dupli-
cates left 771 unique records. After screening titles and abstracts
we identified 21 potentially eligible references. We excluded nine
studies (see Excluded studies). Nine studies are included in the
review. Three studies are awaiting assessment, two of which are
listed as completed but no results are available and one of which
has been terminated for unknown reasons (see Studies awaiting
classification). We did not identify any ongoing studies. Figure 1
shows the flow chart of study retrieval and selection.
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Figure 1. Process for sifting search results and selecting studies for inclusion
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Included studies
For details of the included studies see the Characteristics of
included studies table.
Design
All included studies were randomised trials. Three (33%) were
double-blind, five (56%) were single-blind and one (11%) was an
open-label trial.
Sample sizes
Sample sizes of the included studies ranged from 68 to 599 chil-
dren.
Setting
Most studies were conducted in a secondary or tertiary care setting
in a range of countries, mainly the USA and Northern Europe
(Scandinavia and the Netherlands).
Participants
The participants in all studies were children ranging in age from 0
to 12 years. The percentage of participants who were boys in the
included studies ranged from 52% to 67%. Most studies included
children with uncomplicated ear discharge of less than three weeks
duration; duration of ear discharge was less than 48 hours in two
trials.
Interventions
In the nine included studies a wide range of interventions were
studied. Six trials compared two interventions and three compared
three different interventions. Table 1 provides an overview of in-
terventions and the eight comparison pairs included in this review.
Details of the specific interventions (formulae, dosage, duration)
can be found in the Characteristics of included studies table.
Outcomes
Table 2 summarises whether the included studies did (or did not)
report on our pre-specified outcomes. All outcomes were reported
in at least one study except for the secondary outcome “proportion
of children without other signs of a middle ear infection (ear pain
and fever) at short-term follow-up”.
Funding and conflict of interest
Five studies were either directly funded or financially supported by
pharmaceutical companies (Alcon (three trials), Daiichi, Salvat);
the pharmaceutical companies provided the study medication in
two studies. One study received non-commercial (governmental)
funding; one study was performed without funding.
Excluded studies
We excluded nine articles after reviewing the full text. Reasons for
exclusion are provided in the Characteristics of excluded studies
table.
Risk of bias in included studies
Summaries of the ’Risk of bias’ assessment of the included studies
are presented in Figure 2 and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
The method of random sequence generation was adequately de-
scribed in seven studies (78%) and unclear in two studies (22%).
Allocation concealment
Concealment of allocation was adequately described in five studies
(56%) and unclear in four studies (44%).
Blinding
We judged the risk of bias for blinding of participants and person-
nel (performance bias) as low in four studies (44%) and high in
five studies (56%). We judged the risk of bias for blinding of out-
come assessment (detection bias) as low in seven studies (78%),
unclear in one study (11%) and high in one study (11%).
Incomplete outcome data
We judged the risk of bias for incomplete outcome data as low
in three studies (33%), unclear in two studies (22%) and high in
four studies (44%).
Selective reporting
We judged the risk of bias for selective reporting as low in two
studies (22%). We could not retrieve trial protocols for the re-
maining seven studies (78%) and could therefore not determine
the risk of selective outcome reporting bias for these studies.
Other potential sources of bias
We judged the risk of other potential sources of bias as low in two
studies (22%), unclear in six studies (67%) and high in one study
(11%).
Effects of interventions
See: Summary of findings for the main comparison Antibiotic
eardrops (with or without a corticosteroid) versus oral antibiotics
in children with grommets (ventilation tubes) who develop ear
discharge beyond the immediate postoperative period
We have reported all available outcome data for all comparisons
(those not listed were not available).
1. Antibiotic eardrops (with or without a
corticosteroid) versus oral antibiotics
Primary outcomes
Proportion of patients with resolution of ear discharge at
short-term follow-up
For this outcome, we could use data from only one study (Heslop
2010) (42 randomised children; 42 (100%) included in anal-
ysis). Children treated with antibiotic eardrops (ciprofloxacin)
were more likely to have resolution of ear discharge at one week
than those treated with oral antibiotics (amoxicillin) (ciprofloxa-
cin eardrops versus amoxicillin: 77% versus 30%; risk ratio (RR)
2.58, 95% confidence interval (CI) 1.27 to 5.22, number needed
to treat to benefit (NNTB) 3) (Analysis 1.1; Figure 4).
Figure 4. Forest plot of comparison: 1 Antibiotic eardrops (with or without a corticosteroid) versus oral
antibiotics, outcome: 1.1 Resolution of ear discharge at one week.
Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to imprecise effect
estimates (small sample size).
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Adverse events likely to be related to study medications
We combined data from three studies (Dohar 2006; Goldblatt
1998; vanDongen 2014) (707 randomised children; 705 (99.6%)
included in analysis). The frequency of adverse events did not sig-
nificantly differ between children treated with antibiotic eardrops
with or without corticosteroids and those treated with oral antibi-
otics (RR 0.37, 95% CI 0.12 to 1.09; I² = 88%, random-effects
model) (Analysis 1.2; Figure 5).We also did not find evidence that
the effects differed among subgroups for this outcome.
Figure 5. Forest plot of comparison: 1 Antibiotic eardrops (with or without a corticosteroid) versus oral
antibiotics, outcome: 1.2 Adverse events likely to be related to the use of study medications.
In the sensitivity analysis including only studies judged as low risk
of bias for allocation concealment and incomplete outcome data,
only one study could be included (van Dongen 2014). In this
study, adverse events did not differ between children treated with
antibiotic-corticosteroid eardrops (bacitracin-colistin-hydrocorti-
sone) and those treated with oral antibiotics (RR 0.88, 95% CI
0.51 to 1.52) (Analysis 2.1). It should be noted that 89%of adverse
events associated with antibiotic-corticosteroid eardrops related to
ear pain or discomfort during administration of the drops whereas
86% of adverse events associated with oral antibiotics were gas-
trointestinal symptoms.
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and inconsis-
tency of effect estimates across individual studies.
Serious complications related to middle ear infection
For this outcome, we could use data from one study only (153 ran-
domised children; 153 (100%) included in analysis) (van Dongen
2014). Serious complications related to middle ear infection were
not reported in this study.
Quality of the evidence
The evidence for this outcome was of very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (small sample size and infrequent
occurrence of outcome).
Secondary outcomes
Proportion of patients with resolution of ear discharge at
intermediate-term follow-up
For this outcome, we could use data from three studies (Dohar
2006; Goldblatt 1998; van Dongen 2014) (707 randomised chil-
dren; 465 (66%) included in analysis). In this analysis, one of the
subgroup analyses showed a significant subgroup difference: chil-
dren treated with antibiotic(s)-corticosteroid eardrops were more
likely to have resolution of ear discharge at two to four weeks than
those treated with oral antibiotics and those treated with antibi-
otic-only eardrops (RR 1.59, 95%CI 1.35 to 1.88, I² = 5%, fixed-
effect model; NNTB 8 versus RR 1.00, 95% CI 0.91 to 1.09,
respectively) (Analysis 1.3).
In the sensitivity analysis including only studies judged as low risk
of bias for allocation concealment and incomplete outcome data,
one study was included (vanDongen 2014). Children treated with
antibiotic-corticosteroid eardrops (bacitracin-colistin-hydrocorti-
sone) were more likely to have resolution of ear discharge at two
weeks than those treated with oral antibiotics (bacitracin-colistin-
18Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
hydrocortisone eardrops versus amoxicillin-clavulanate: 95% ver-
sus 56%; RR 1.70, 95% CI 1.38 to 2.08, NNTB 3) (Analysis 2.2;
Figure 6).
Figure 6. Forest plot of comparison: 2 Sensitivity analysis - Antibiotic eardrops (with or without a
corticosteroid) versus oral antibiotics, outcome: 2.2 Resolution of ear discharge at two weeks.
Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to study limitations.
Duration of ear discharge
For this outcome, we could use data from two studies (Dohar
2006; vanDongen 2014) (233 randomised children; 232 (99.6%)
included in analysis). Children treated with antibiotic-corticos-
teroid eardrops had a shorter duration of ear discharge than those
treated with oral antibiotics; median 4 days (range 1 to 28) versus
5 days (range 1 to 36) (van Dongen 2014) and median 4 days
(range not reported) versus 7 days (range not reported) (Dohar
2006), respectively.We did not deem sensitivity analysis to be use-
ful because of the low number of studies.
Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to study limitations.
Proportion of patients with chronic ear discharge
For this outcome, we could use data from one study only (153 ran-
domised children; 148 (97%) included in analysis) (van Dongen
2014). The proportion of children with chronic ear discharge did
not differ significantly between children treated with antibiotic-
corticosteroid eardrops (bacitracin-colistin- hydrocortisone) and
those treated with oral antibiotics (RR 0.20, 95%CI 0.02 to 1.67)
(Analysis 1.4).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to due to study limitations and
imprecise effect estimate (infrequent occurrence of outcome).
Ear discharge recurrences
For this outcome, we could use data from one study only (153 ran-
domised children; 148 (97%) included in analysis) (van Dongen
2014). Children treated with antibiotic-corticosteroid eardrops
had fewer recurrences of ear discharge during sixmonths follow-up
than those treated with oral antibiotics: median 0 episodes (range
0 to 9) versus 1 episode (range 0 to 6) (median difference -1, P =
0.03).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to due to study limitations and
imprecise effect estimate (small sample size).
Proportion of patients with tube blockage
We combined data from two studies (122 randomised children;
121 (99%) included in analysis) (Dohar 2006; Heslop 2010). The
proportion of children with tube blockage did not differ signifi-
cantly between those treated with antibiotic eardrops with or with-
out corticosteroids and oral antibiotics (RR 1.20, 95% CI 0.33
to 4.45; I² = 0%, fixed-effect model) (Analysis 1.5). We did not
deem subgroup and sensitivity analyses to be useful because of the
low number of studies and included children.
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Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and imprecise
effect estimate (small sample size and infrequent occurrence of
outcome).
Health-related quality of life
For this outcome, we could use data from one study only (153 ran-
domised children; 153 (100%) included in analysis) (van Dongen
2014). This study measured generic quality of life with the Child
Heath Questionnaire and disease-specific quality of life with the
Otitis Media-6 questionnaire. At two weeks, the change in generic
health-related quality of life scores did not differ significantly be-
tween those treated with antibiotic-corticosteroid eardrops and
those treated with oral antibiotics. The changes in Otitis Media-6
total score (range 6 to 42) at two weeks were small, but favoured
the antibiotic-corticosteroid eardrops group (difference in median
change between treatment groups: -2, P < 0.01).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and imprecise
effect estimate (small sample size).
Hearing levels
Two studies provided information on this outcome. Dohar 2006
(79 children) compared antibiotic-corticosteroid eardrops (cipro-
floxacin-dexamethasone) with oral antibiotics (amoxicillin-clavu-
lanic acid) and stated that “neither treatment group had any neg-
ative effect on patient audiometry”. Goldblatt 1998 (474 ran-
domised children) performed audiometry in only a small subset
of randomised children (56, i.e. 12%) and reported improvement
in detecting air-conducted sound in 19/28 (68%) children treated
with antibiotic eardrops (ofloxacin) versus 9/26 (35%) of those
treated with oral antibiotics (amoxicillin-clavulanic acid).
Quality of the evidence
The evidence for this outcome was of very low quality; we down-
graded it from high to very low quality due to study limitations,
imprecise effect estimate (small sample size) and inconsistency of
effect estimates across studies.
2. Antibiotic eardrops (with or without a
corticosteroid) versus corticosteroid eardrops
Primary outcomes
Adverse events likely to be related to study medications
For this outcome, we could use data from only one study
(331 randomised children; 331 (100%) included in analysis)
(NCT01404611). Frequency of adverse events did not signifi-
cantly differ between children treated with antibiotic-corticos-
teroid eardrops (ciprofloxacin-fluocinolone acetonide), antibiotic
eardrops (ciprofloxacin) and corticosteroid eardrops (fluocinolone
acetonide): 0/111 (0%) versus 1/112 (1%) versus 2/108 (2%),
respectively.
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to moderate quality due to imprecise effect estimate
(small sample size and infrequent occurrence of outcome).
Serious complications related to middle ear infection
For this outcome, we could use data from only one study
(331 randomised children; 331 (100%) included in analysis)
(NCT01404611). Serious complications related to middle ear in-
fection were reported infrequently and did not significantly differ
between children treated with antibiotic-corticosteroid eardrops
(ciprofloxacin-fluocinolone acetonide), antibiotic eardrops (cipro-
floxacin) and corticosteroid eardrops (fluocinolone acetonide): 0/
111 (0%) versus 1/112 (1%; acute mastoiditis) versus 0/108 (0%),
respectively.
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to imprecise effect estimate (small
sample size and infrequent occurrence of outcome).
Secondary outcomes
Duration of ear discharge
For this outcome, we could use data from only one study
(331 randomised children; 331 (100%) included in analysis)
(NCT01404611). Children treated with corticosteroid eardrops
(fluocinolone acetonide) had a longer duration of ear discharge
than those treated with antibiotic-corticosteroid eardrops (cipro-
floxacin-fluocinolone acetonide) and antibiotic eardrops (cipro-
floxacin): median 22 days (95% CI 14 to 22) versus 5 days (95%
CI 4 to 6) versus 7 days (95% CI 6 to 8), respectively.
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Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to imprecise effect
estimate (small sample size).
3. Antibiotic eardrops (with or without a
corticosteroid) versus saline rinsing of the ear canal
Primary outcomes
Proportion of patients with resolution of ear discharge at
short-term follow-up
For this outcome, we could use data from only one study (48
randomised children; 48 (100%) included in analysis) (Heslop
2010). Children treated with antibiotic eardrops (ciprofloxacin)
were more likely to have resolution of ear discharge at one week
than those treatedwith saline rinsing of the ear canal (ciprofloxacin
eardrops versus saline rinsing: 77% versus 46%; RR 1.67, 95%
CI 1.04 to 2.69, NNTB 4) (Analysis 3.1).
Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to imprecise effect
estimate (small sample size).
Secondary outcomes
Proportion of patients with tube blockage
For this outcome, we could use data from only one study (48
randomised children; 48 (100%) included in analysis) (Heslop
2010). The proportion of children with tube blockage did not
differ significantly between those treated with antibiotic eardrops
(ciprofloxacin) and saline rinsing of the ear canal (RR 1.77, 95%
CI 0.32 to 9.67) (Analysis 3.2).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to imprecise effect estimate (small
sample size and infrequent occurrence of outcome).
4. Antibiotic eardrops (with or without a
corticosteroid) versus no treatment
Primary outcomes
Serious complications related to middle ear infection
For this outcome, we could use data from only one study (153 ran-
domised children; 153 (100%) included in analysis) (van Dongen
2014). Serious complications related to the middle ear infection
did not occur in this study.
Quality of the evidence
The evidence for this outcome was of very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (small sample size and infrequent
occurrence of outcome).
Secondary outcomes
Proportion of patients with resolution of ear discharge at
intermediate-term follow-up
For this outcome, we could use data from only one study (153 ran-
domised children; 151 (99%) included in analysis) (van Dongen
2014). Children treated with antibiotic-corticosteroid eardrops
(hydrocortisone-bacitracin-colistin) were more likely to have res-
olution of ear discharge at two weeks than those who did not re-
ceive treatment (bacitracin-colistin-hydrocortisone eardrops ver-
sus no treatment: 95% versus 45%; RR 2.09, 95% CI 1.62 to
2.69, NNTB 2) (Analysis 4.1).
Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to study limitations.
Duration of ear discharge
For this outcome, we could use data from only one study (153 ran-
domised children; 147 (96%) included in analysis) (van Dongen
2014). Children treated with antibiotic-corticosteroid eardrops
(hydrocortisone-bacitracin-colistin) had a shorter duration of ear
discharge than those who did not receive treatment: median 4 days
(range 1 to 28) versus 12 days (range 1 to 159), respectively.
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Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to study limitations.
Proportion of patients with chronic ear discharge
For this outcome, we could use data from only one study
(153 randomised children; 147 (96%) included in analysis) (van
Dongen 2014). Children treated with antibiotic-corticosteroid
eardrops (hydrocortisone-bacitracin-colistin) were less likely to
have chronic ear discharge than those who did not receive treat-
ment (RR 0.08, 95% CI 0.01 to 0.62, NNTB 7) (Analysis 4.2).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to due to study limitations and
imprecise effect estimate (infrequent occurrence of outcome).
Ear discharge recurrences
For this outcome, we could use data from only one study (153 ran-
domised children; 147 (96%) included in analysis) (van Dongen
2014). The median number of recurrent ear discharge episodes
during six months follow-up did not differ significantly between
children treated with antibiotic-corticosteroid eardrops (hydro-
cortisone-bacitracin-colistin) and those who did not receive treat-
ment: median 0 episodes (range 0 to 9) versus 1 episode (range 0
to 5) (median difference -1, P = 0.26).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and imprecise
effect estimate (small sample size).
Health-related quality of life
For this outcome, we could use data from only one study (153 ran-
domised children; 153 (100%) included in analysis) (van Dongen
2014). This study measured generic quality of life with the Child
Heath Questionnaire and disease-specific quality of life with the
Otitis Media-6 questionnaire. At two weeks, the change in generic
health-related quality of life scores did not differ significantly be-
tween children treated with antibiotic-corticosteroid eardrops (hy-
drocortisone-bacitracin-colistin) and those who did not receive
treatment. The changes in Otitis Media-6 total score (range 6
to 42) at two weeks were small but favoured antibiotic-corticos-
teroid eardrops (difference in median difference between treat-
ment groups: -1.5, P < 0.01).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and imprecise
effect estimate (small sample size).
5. Antibiotic(s)-corticosteroid eardrops versus
antibiotic eardrops
Primary outcomes
Proportion of patients with resolution of ear discharge at
short-term follow-up
We combined data from two studies (800 randomised chil-
dren; 590 (74%) included in analysis) (Roland 2003; Roland
2004). Children treated with antibiotic-corticosteroid eardrops
were more likely to have resolution of ear discharge at less than
two weeks than those treated with antibiotic eardrops (35% versus
20%; RR 1.76, 95% CI 1.33 to 2.31, I2 = 0%, fixed-effect model;
NNTB 12) (Analysis 5.1). We did not deem sensitivity analysis to
be useful because of the low number of studies.
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and risk of
publication bias (two studies were completed but the results were
not available, one study was terminated for unknown reasons, see
Characteristics of studies awaiting classification).
Adverse events likely to be related to study medications
We combined data from three studies (1023 randomised chil-
dren; 1023 (100%) included in analysis) (NCT01404611; Roland
2003; Roland 2004). Adverse events did not differ significantly
between children treated with antibiotic-corticosteroid eardrops
and those treated with antibiotic eardrops (RR 0.86, 95% CI 0.55
to 1.32; I2 = 0%, fixed-effect model) (Analysis 5.2). The data did
not allow us to perform subgroup analyses.
In the sensitivity analysis, where we only included studies judged
as low risk of bias for allocation concealment and incomplete out-
come data, data from one study could be used (NCT01404611).
The results from sensitivity analysis were comparable with the ef-
fect estimate observed in our main analysis (Analysis 6.1).
Quality of the evidence
The evidence for this outcome was of low quality; we down-
graded it from high to low quality due to imprecise effect estimate
(small sample size) and risk of publication bias (two studies were
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completed but results were not available, one study was termi-
nated for unknown reasons, see Characteristics of studies awaiting
classification).
Serious complications related to middle ear infection
For this outcome, we could use data from two studies (822
randomised children; 822 (100%) included in analysis) (
NCT01404611; Roland 2004). Serious complications related to
middle ear infection were reported infrequently and did not dif-
fer significantly between children treated with antibiotic-corticos-
teroid eardrops and those treated with antibiotic eardrops: 0/408
versus 1/414 (mastoiditis), respectively.We did not deem sensitiv-
ity analysis to be useful because of the low number of studies and
events.
Quality of the evidence
The evidence for this outcome was of very low quality; we down-
graded it from high to very low quality due to imprecise effect es-
timate (small sample size and infrequent occurrence of outcome)
and risk of publication bias (two studies were completed but re-
sults were not available, one study was terminated for unknown
reasons, see Characteristics of studies awaiting classification).
Secondary outcomes
Proportion of patients with resolution of ear discharge at
intermediate-term follow-up
We combined data from two studies (800 randomised children;
590 (74%) included in analysis) (Roland 2003; Roland 2004).
The proportion of children with resolution of ear discharge at two
to four weeks did not differ significantly between children with
antibiotic-corticosteroid eardrops and those treatedwith antibiotic
eardrops (RR 1.09, 95% CI 0.90 to 1.31; I2 = 84%, random-
effects model) (Analysis 5.3). We did not deem sensitivity analysis
to be useful because of the low number of studies.
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and risk of
publication bias (two studies were completed but results were not
available, one study was terminated for unknown reasons, see
Characteristics of studies awaiting classification).
Duration of ear discharge
For this outcome, we could use data from three studies
(1023 randomised children; 813 (79%) included in analysis)
(NCT01404611; Roland 2003; Roland 2004). The data did not
allow pooling, but study results showed a small but consistent dif-
ference in the number of days with ear discharge in favour of an-
tibiotic-corticosteroid eardrops (mean duration 4.22 versus 5.31
days; 4 versus 6 days and 5 versus 7 days, respectively).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and risk of
publication bias (two studies were completed but results were not
available, one study was terminated for unknown reasons, see
Characteristics of studies awaiting classification).
Proportion of patients with tube blockage
For this outcome, we could use data from two studies (800 ran-
domised children; 766 (96%) included in analysis) (Roland 2003;
Roland 2004). The proportion of children with tube blockage
did not differ significantly between those treated with antibi-
otic eardrops with or without a corticosteroid; one study (201
randomised children; 167 (83%) included in analyses) reported
that “there were no significant differences between the two treat-
ments in continued tympanostomy tube patency (> 97% in both
groups)” (Roland 2003), whereas the proportions of children with
tube blockage in the other study were 1/297 and 0/302, respec-
tively (Roland 2004).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and risk of
publication bias (two studies were completed but results were not
available, one study was terminated for unknown reasons, see
Characteristics of studies awaiting classification).
Hearing levels
Two studies provided information on this outcome. In one study
(201 randomised children; number of children analysed un-
known) it was stated that “audiometric examinations performed
on patients exiting from the study revealed no clinically meaning-
ful or statistically significant (P = 0.3038) worsening of the speech
reception threshold in any patient” (Roland 2003), whereas in the
other study (599 randomised children; number of children anal-
ysed unknown) it was stated that “no clinically relevant or statis-
tically significant differences in mean change of speech recogni-
tion threshold from baseline or decrease in hearing from baseline
were observed after treatment with either ciprofloxacin/dexam-
ethasone or ofloxacin, based on bone and air conduction audiom-
etry” (Roland 2004).
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Quality of the evidence
The evidence for this outcome was of very low quality; we down-
graded it from high to very low quality due to due to study limi-
tations, imprecise effect estimate and risk of publication bias (two
studies were completed but results were not available, one study
was terminated for unknown reasons, see Characteristics of studies
awaiting classification).
6. Oral antibiotics versus saline rinsing of the ear
canal
Primary outcomes
Proportion of patients with resolution of ear discharge at
short-term follow-up
For this outcome, we could use data from only one study (46
randomised children; 46 (100%) included in analysis) (Heslop
2010). The proportion of children with resolution of ear discharge
at one week did not differ significantly between children treated
with oral antibiotics and those treated with saline rinsing of the
ear canal (RR 0.65, 95% CI 0.30 to 1.43) (Analysis 7.1).
Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to imprecise effect
estimate (small sample size).
Secondary outcomes
Proportion of patients with tube blockage
For this outcome, we could use data from only one study (46 ran-
domised children; 46 (100%) included in analysis) (Heslop 2010).
The proportion of children with tube blockage did not differ sig-
nificantly differ between children treated with oral antibiotics and
those treated with saline rinsing of the ear canal (RR 1.95, 95%
CI 0.36 to 10.58) (Analysis 7.2).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to imprecise effect estimate (small
sample size and infrequent occurrence of outcome).
7. Oral antibiotics versus placebo or no treatment
Primary outcomes
Proportion of patients with resolution of ear discharge at
short-term follow-up
For this outcome, we could use data from only one study (79
randomised children; 79 (100%) included in analysis) (Ruohola
2003). Children treated with oral antibiotics (amoxicillin-clavu-
lanate) were more likely to have resolution of ear discharge at
less than two weeks than those treated with placebo (amoxicillin-
clavulanate versus placebo: 72% versus 33%; RR 2.21, 95% CI
1.36 to 3.60, NNTB 3) (Analysis 8.1).
Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to imprecise effect
estimate (small sample size).
Adverse events likely to be related to study medications
For this outcome, we could use data fromonly one study (Ruohola
2003) (79 randomised children; 79 (100%) included in analysis).
Adverse events did not differ significantly between children treated
with oral antibiotics and those treated with placebo (RR 1.71,
95% CI 0.69 to 4.25) (Analysis 8.2).
Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to imprecise effect
estimate (small sample size).
Serious complications related to middle ear infection
For this outcome, we could use data from two studies (233 ran-
domised children; 233 (100%) included in analysis) (Ruohola
2003; vanDongen 2014). In both studies no serious adverse events
related to middle ear infection occurred.
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to imprecise effect estimate (small
sample size and infrequent occurrence of outcome).
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Secondary outcomes
Proportion of patients with resolution of ear discharge at
intermediate-term follow-up
For this outcome, we could use data from only one study (154 ran-
domised children; 152 (99%) included in analysis) (van Dongen
2014). The proportion of children with resolution of ear discharge
at two weeks did not differ significantly differ between children
treated with oral antibiotics and those who did not receive treat-
ment (RR 1.23, 95% CI 0.90 to 1.69) (Analysis 8.3).
Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to study limitations.
Duration of ear discharge
For this outcome, we could use data from two studies (233 ran-
domised children; 226 (97%) included in analysis) (Ruohola
2003; van Dongen 2014). The data did not allow pooling, but
study results showed a significant difference in the number of days
with ear discharge in favour of oral antibiotics (median duration
3 versus 8 days and median duration 5 versus 12 days).
Quality of the evidence
The evidence for this outcome was of moderate quality; we down-
graded it from high to moderate quality due to imprecise effect
estimate (small sample size).
Proportion of patients with chronic ear discharge
For this outcome, we could use data from only one study (154 ran-
domised children; 147 (95%) included in analysis) (van Dongen
2014). The proportion of children with chronic ear discharge did
not differ significantly differ between children treated with oral
antibiotics and those who did not receive treatment (RR 0.41,
95% CI 0.15 to 1.11) (Analysis 8.4).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to due to study limitations and
imprecise effect estimate (infrequent occurrence of outcome).
Ear discharge recurrences
For this outcome, we could use data from only one study (154 ran-
domised children; 147 (95%) included in analysis) (van Dongen
2014). The median number of ear discharge recurrences during
six months follow-up did not differ significantly between children
treated with oral antibiotics and those who did not receive treat-
ment: median 1 episode (range 0 to 6) versus 1 episode (range 0
to 5) (median difference 0, P = 0.21).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and imprecise
effect estimate (small sample size).
Proportion of patients with tube extrusion
For this outcome, we could use data from one study (79 ran-
domised children; 79 (100%) included in analysis) (Ruohola
2003). The proportion of children with tube extrusion did not
differ significantly between children treated with oral antibiotics
and those treated with placebo (RR 0.51, 95% CI 0.05 to 5.43)
(Analysis 8.5).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to imprecise effect estimate (small
sample size and infrequent occurrence of outcome).
Health-related quality of life
For this outcome, we could use data from only one study (154 ran-
domised children; 154 (100%) included in analysis) (van Dongen
2014). This study measured generic quality of life with the Child
Heath Questionnaire and disease-specific quality of life with the
Otitis Media-6 questionnaire. At two weeks, the change in generic
health-related quality of life scores and Otitis Media-6 total score
did not differ significantly between children treated with oral an-
tibiotics and those who did not receive treatment.
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to low quality due to study limitations and imprecise
effect estimate (small sample size).
8. Oral corticosteroids versus placebo
Primary outcomes
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Proportion of patients with resolution of ear discharge at
short-term follow-up
For this outcome, we could use data from only one study (70
randomised children; 50 (71%) included in analysis) (Ruohola
1999). The proportion of children with resolution of ear discharge
within two weeks did not differ significantly between children
treated with oral corticosteroids and those treated with placebo as
adjunctive therapy to oral antibiotics (RR 1.08, 95% CI 0.92 to
1.26) (Analysis 9.1).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to moderate quality due to study limitations and
imprecise effect estimate (small sample size).
Adverse events likely to be related to the use of study
medications
For this outcome, we could use data from only one study (70
randomised children; 50 (71%) included in analysis) (Ruohola
1999). Adverse events did not differ significantly between children
treated with oral corticosteroids and those treated with placebo as
adjunctive therapy to oral antibiotics (RR 0.23, 95% CI 0.01 to
4.63) (Analysis 9.2).
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to moderate quality due to study limitations and
imprecise effect estimate (small sample size).
Serious complications related to middle ear infection
For this outcome, we could use data from only one study (70
randomised children; 50 (71%) included in analysis) (Ruohola
1999). In this study serious adverse events related to middle ear
infection did not occur.
Quality of the evidence
The evidence for this outcome was of very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (small sample size and infrequent
occurrence of outcome).
Secondary outcomes
Duration of ear discharge
For this outcome, we could use data from only one study (70
randomised children; 50 (71%) included in analysis) (Ruohola
1999). In this study, a small but statistically significant difference
in the median number of days with ear discharge in favour of oral
corticosteroids (prednisolone) was observed: median duration 1
versus 3 days.
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to moderate quality due to study limitations and
imprecise effect estimate (small sample size).
Ear discharge recurrences
For this outcome, we could use data from only one study (70
randomised children; 50 (71%) included in analysis) (Ruohola
1999). The number of recurrences of ear discharge did not differ
significantly between children treatedwith oral corticosteroids and
those treatedwith placebo as adjunctive therapy to oral antibiotics:
1/23 versus 3/27, respectively.
Quality of the evidence
The evidence for this outcome was of low quality; we downgraded
it from high to moderate quality due to study limitations and
imprecise effect estimate (small sample size).
D I S C U S S I O N
Summary of main results
Nine studies (2132 children) were included in this review, evaluat-
ing a range of interventions for children aged under 12 years with
grommets who developed acute ear discharge beyond the imme-
diate postoperative period. We judged the risk of bias to be low to
moderate in most studies.
Current evidence indicates that antibiotic eardrops (with or
without a corticosteroid) are more effective than the following:
• Oral antibiotics in terms of resolution of ear discharge at
one week and two weeks (moderate-quality evidence), duration of
ear discharge (moderate-quality evidence), ear discharge
recurrences (low-quality evidence) and disease-specific quality of
life (low-quality evidence), but not in terms chronic ear discharge
(low-quality evidence), tube blockage (low-quality evidence),
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generic quality of life (low-quality evidence) or hearing (low-
quality evidence). Frequency of adverse events did not
significantly differ between children treated antibiotic eardrops
and those treated with oral antibiotics (low-quality evidence).
• Corticosteroid eardrops in terms of duration of ear
discharge (moderate-quality evidence). Frequency of adverse
events did not significantly differ between children treated with
topical antibiotics and those treated with topical corticosteroids
(low-quality evidence).
• No treatment in terms of resolution of ear discharge at two
weeks (moderate-quality evidence), duration of ear discharge
(moderate-quality evidence), chronic ear discharge (low-quality
evidence) and disease-specific quality of life (low-quality evidence),
but not in terms of ear discharge recurrences (low-quality
evidence) and generic quality of life (low-quality evidence).
There is also some evidence that antibiotic eardrops are more ef-
fective than saline rinsing of the ear canal in terms of resolution
of ear discharge at one week (moderate-quality evidence), but not
in terms of tube blockage (low-quality evidence). These findings
should, however, be interpreted with caution since a trivial or clin-
ically irrelevant difference between antibiotic eardrops and saline
rinsing of the ear canal cannot be excluded.
We found low-quality evidence that eardrops containing a com-
bination of an antibiotic and a corticosteroid are more effective
than antibiotic eardrops in terms of resolution of ear discharge at
short-term follow-up and duration of ear discharge, but not in
terms of resolution of ear discharge at intermediate-term follow-
up and tube blockage. These findings should, however, be inter-
preted with caution because of a substantial risk of publication
bias.
Overall completeness and applicability of
evidence
The children participating in the nine studies included in this re-
view represent those most commonly encountered in clinical prac-
tice, that is children below 12 years of age with grommets who de-
veloped uncomplicated ear discharge of less than three weeks du-
ration. The studies evaluate the full range of interventions that are
most commonly used in day-to-day practice, including antibiotic
eardrops with or without a corticosteroid, oral antibiotics, saline
rinsing of thee ar canal and initial observation. As such, the overall
degree of completeness is high.
Quality of the evidence
The quality of the evidence for the primary outcomes looking at
effectiveness in the studies comparing antibiotic eardrops versus
other interventions was moderate. The quality of evidence for the
safety outcomes and secondary outcomes looking at effectiveness
in the studies comparing antibiotic eardrops versus other interven-
tions was mostly low or very low. The facts that all studies favoured
antibiotic eardrops over other interventions and that the differ-
ence between treatments was large (in favour of eardrops) increase
our confidence in the review findings; it is therefore unlikely that
further research will change our confidence in the effects observed.
Potential biases in the review process
We used an extensive search strategy without language or publica-
tion restrictions; it is therefore unlikely that we have missed rele-
vant studies. For the comparison antibiotic-corticosteroid eardrops
versus antibiotic-only eardrops three studies are, however, awaiting
classification (see Characteristics of studies awaiting classification).
This may impact the findings substantially and the results of this
comparison should therefore be interpreted with caution.
Two authors independently undertook data extraction and ’Risk
of bias’ assessment and we strictly adhered to the instructions in
the Cochrane Handbook for Systematic Reviews of Interventions (
Handbook 2011). Three review authors are, however, authors of
the included study comparing antibiotic-corticosteroid eardrops
with oral antibiotics and no treatment (van Dongen 2014). To
avoid potential conflict of interest, the two other review authors
reviewed the eligibility and performed the ’Risk of bias’ assessment
and data extraction for this study.
In this review, we have assigned a unitary weight for each ad-
verse event. Although we followed our published protocol when
analysing adverse events, categorising these by severity may have
beenmore appropriate.We encourage researchers to report adverse
events by severity in future trials in this field and we will consider
this approach when updating the current review.
Finally, downgrading of the quality of evidence according to sam-
ple/effect size, i.e. the determination of ’imprecise effect estimate’,
was not based on a predetermined criterion but rather based on a
post hoc subjective interpretation of the review authors.
Agreements and disagreements with other
studies or reviews
Since the 2006 Cochrane Review on this topic (Vaile 2006), four
new studies have been published and included in this new review.
This provides a robust evidence base for the treatment of children
with grommets who develop ear discharge beyond the immediate
postoperative period. Our main findings are in agreement with
a recently published review on this topic (Chee 2016), and with
the clinical practice guideline ’Tympanostomy tubes in children’
issued by the American Academy of Otolaryngology - Head and
Neck Surgery (Rosenfeld 2013), but they are not in line with
current National Institute for Health and Care Excellence (NICE)
recommendations to treat this condition as an episode of acute
27Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
otitismedia (initial observation for uncomplicated disease and oral
antibiotics for complicated or persisting disease) (NICE 2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides robust evidence that antibiotic eardrops are
more effective than oral antibiotics, corticosteroid eardrops and
no treatment in children with grommets who develop acute ear
discharge beyond the immediate postoperative period. We hope
that this review will help a consensus to be reached across countries
regarding first-line treatment for children with uncomplicated ear
discharge occurring at least two weeks following grommet (venti-
lation tube) insertion.
This review provides no evidence to suggest that effectiveness
varies across different types or formulations of antibiotic eardrops.
Antibiotic eardrops covering the otopathogens that most com-
monly cause ear discharge in children with grommets (i.e. non-ty-
peableHaemophilus influenzae,Staphylococcus aureus, Pseudomonas
aeruginosa,Streptococcus pneumoniae andMoraxella catarrhalis) are
likely to be equally effective.
Quinolones are considered non-ototoxic (Pappas 2006) and
are currently the recommended ototopical agent in the USA
(Rosenfeld 2013). However, these eardrops are not widely avail-
able in many countries (in contrast to ophthalmic formulations)
and widespread use of quinolones has been suggested to induce
antimicrobial resistance and fungal overgrowth, especially when
used for a prolonged duration.
Animal studies have shown that aminoglycoside-containing
eardrops are potentially ototoxic. The evidence in humans with an
infected middle ear is, however, debated. Consensus statements by
various ENT professional organisations have therefore suggested
that “in patients with a discharging ear in the presence of a perfo-
ration or patent grommet, if a topical aminoglycoside is used, this
should only be in the presence of obvious infection...[and] for no
longer than two weeks” (Mylanus 2004; Phillips 2007).
Implications for research
We feel that this review answers the most important questions
around the best management of children with grommets who de-
velop ear discharge beyond the immediate postoperative period.
Current evidence comparing antibiotic eardrops and saline rinsing
of the ear canal is, however, limited and inconclusive. Future trials
comparing these treatment strategies may therefore have an im-
pact on the current review findings. Also, there is a need for well-
designed trials comparing antibiotic-corticosteroid eardrops and
eardrops containing antibiotics only because the current evidence
is of low quality and carries a substantial risk of publication bias.
A further unresolved issue is that of the safety of both quinolone
and non-quinolone antibiotic eardrops; implementation of the
findings of this review will likely increase the use of antibiotic
eardrops in children with grommets. We therefore emphasise the
importance of continuous active surveillance of adverse effects
including antimicrobial resistance, fungal overgrowth and sen-
sorineural hearing loss associated with antibiotic eardrops.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dohar 2006
Methods Allocation: randomised
Design: parallel, outcome-assessor blinded
Participants Number: 80 (79 included in analyses)
Age: 6 months to 8 years; mean age 1.9 years (SD 1.7 years)
Gender: 42 boys (53%), 38 girls (47%)
Setting: secondary care, 6 ENT surgeons located in the USA participated as investigators
Eligibility criteria: children aged 6 months to 12 years with patent grommets and a
clinical diagnosis of uncomplicated AOMwith ear discharge (drainage visible to parent/
guardian) of ≤ 3 weeks duration in one or both ears
Exclusion criteria: ear discharge of ≥ 3 weeks duration; acute or malignant otitis ex-
terna; known or suspected fungal or mycobacterial ear infections; history of or active viral
infections of the tympanic membrane; mastoiditis; infections requiring systemic antibi-
otics; otologic surgery in the previous year (except that confined to tympanicmembrane);
children with diabetes, immunosuppressive disorders, acute/chronic renal disease, active
hepatitis, chronic nasal obstruction and/or persistent rhinorrhoea, complicating struc-
tural anomalies, known/suspected quinolone hypersensitivity, menarche (girls); previous
history of chronic diarrhoea or pseudomembranous colitis; current or previous history
of cholestatic jaundice or hepatic dysfunction; current diagnosis of mononucleosis; use
of topical (otic or ophthalmic) corticosteroids or antibiotics concurrently or within the
preceding 3 days, systemic corticosteroids within the preceding 7 days, inhaled corti-
costeroids at doses of 800 g/day, topical antibiotics for skin infections within the pre-
ceding 7 days, topical otic analgesics/anaesthetics or antiseptic washes, or nonsteroidal
anti-inflammatory drugs, with the exception of oral acetaminophen for relief of pain;
concurrent administration of allopurinol or probenecid
Interventions Intervention group: antibiotic-corticosteroid eardrops; ciprofloxacin (0.3%)/dexam-
ethasone (0.1%) otic suspension, 4 drops twice daily for 7 days in the affected ear(s)
Comparator group: oral antibiotics; amoxicillin/clavulanic acid oral suspension; 90mg/
kg per day divided into 2 doses for 10 days
Use of additional interventions: in both treatment groups, the ear canal was cleaned
of all fluid and debris via suction (aural toilet) at baseline (and possibly during follow-
up visits)
Outcomes Primary outcomes: 1. time to cessation of ear discharge (parent-reported); 2. clinical
cure (defined as absence of ear discharge as assessed by investigator) at TOC visit (18 to
21 days)
Secondary outcomes: adverse events (assessed during follow-up visits and by parental
report), audiometry at TOC visit, microbiologic response
Funding sources This study was supported by a grant from Alcon Research Ltd (Fort Worth, TX)
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Dohar 2006 (Continued)
Declarations of interest Dr Dohar, Giles, Bikhazi, Carroll, Moe and Reese are independent physicians who
received compensation from the sponsor for the study expenses but received no other
financial incentives. Dr Roland is an independent physician who is paid by the sponsor
for services as a medical monitor and consultant
Notes Participants lost to follow-up total: 1/80 (1%)
Participants lost to follow-up intervention group: 0/40 (0%); 1 child discontinued
the study because of tube obstruction in the study ear but was included in ITT analysis
Participants lost to follow-up comparator group: 1/41 (2%); 1 child discontinued
the study because of dermatitis and diarrhoea
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were sequentially assigned
to treatment according to a randomization
code provided by theAlconBiostatistics de-
partment. The randomization was blocked
within center to ensure balanced treatment
groups within each center.”
Allocation concealment (selection bias) Unclear risk Method not described
The randomisation was blocked within a
centre to ensure balanced treatment groups
within each centre. It is, however, unclear
how large these blocks were, i.e. it is unclear
if the person performing the randomisation
procedure could predict treatment alloca-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Outcome assessor-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor-blinded; those conduct-
ing the clinical observations were unaware
of the treatment assignments. However,
time to cessation of otorrhoea and adverse
events were recorded from parental diaries
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1/80 (1%) children were excluded from
analyses; antibiotic-corticosteroid eardrops
group: 0/39 (0%), oral antibiotics group:
1/41 (2%)
Children with pre-therapy culture of pure
yeast, P. aeruginosa or group A streptococci
were ’discontinued’ from study and started
on alternative therapy. It is unclear how
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Dohar 2006 (Continued)
many children were excluded from analysis
Selective reporting (reporting bias) Unclear risk Protocol was not available; insufficient in-
formation to permit a judgement of low or
high risk
Other bias Low risk Baseline characteristics: balanced
ITT analysis: performed
Sample size calculations: performed
Use of co-interventions: similar across
groups (aural toilet)
Goldblatt 1998
Methods Allocation: randomised
Design: parallel, outcome-assessor blinded
Participants Number: 474 (286 included in analyses)
Age: 1 to 12 years; mean age 3.6 years
Gender: 166 boys (58%), 120 girls (42%)
Setting: secondary care, 36 centres in the USA and 1 centre in Chile
Eligibility criteria: children aged 1 to 12 years with patent grommets andmucopurulent
or purulent ear discharge of presumed bacterial origin for less than 3 weeks
Exclusion criteria: positive culture for P. aeruginosa and fungus as sole pathogen in
final otorrhoea culture and positive culture for group A beta-haemolytic streptococcus,
menarche (girls)
Interventions Intervention group: antibiotic eardrops; ofloxacin (0.3%) otic suspension, 0.25 ml
twice daily for 10 days in the affected ear(s)
Comparator group: oral antibiotics; amoxicillin/clavulanic acid oral suspension; 40mg/
kg per day (25 mg/kg/day in children under 2 years of age if they developed diarrhoea)
divided into 3 doses for 10 days
Use of additional interventions: not described
Outcomes Primary outcome: clinical response (cure defined as absence of ear discharge as assessed
by investigator at follow-up visits at 4 to 6 days, 11 to 13 days, 17 to 20 days)
Secondary outcomes: adverse events (assessed during follow-up visits), audiometry at
17 to 20 days visit, microbiologic response
Funding sources The study was sponsored by the Daiichi Pharmaceutical Corporation
Declarations of interest None stated
Notes Participants lost to follow-up total: 188/474 (40%) excluded from analyses
Participants lost to follow-up intervention group: 88/228 (39%) excluded from anal-
yses
Participants lost to follow-up comparator group: 100/246 (41%) excluded from anal-
yses
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Goldblatt 1998 (Continued)
Main reason for exclusion was positive culture for P. aeruginosa as a sole pathogen
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Outcome assessor-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor-blinded; those conduct-
ing the clinical observations were unaware
of the treatment assignments
Incomplete outcome data (attrition bias)
All outcomes
High risk 188/474 (40%) children excluded from
analyses; antibiotic eardrops group: 88/
228 (39%), oral antibiotics group: 100/246
(41%)
Main reason for exclusion was positive cul-
ture for P. aeruginosa as a sole pathogen
Selective reporting (reporting bias) Unclear risk Protocol was not available; insufficient in-
formation to permit a judgement of low or
high risk
Other bias High risk Baseline characteristics: balanced
ITT analysis: not performed
Sample size calculations: not performed
Use of co-interventions: not described
Heslop 2010
Methods Allocation: randomised
Design: parallel, outcome-assessor blinded
Participants Number: 68 (68 included in analyses)
Age: aged below 10 years; mean age 22 months
Gender: 40 boys (59%), 28 girls (41%)
Setting: secondary care, ENT outpatient clinic, Denmark
Eligibility criteria: Caucasian children aged below 10 years with grommets in situ and
a first episode of ear discharge after grommets insertion
Exclusion criteria: otorrhoea due to other ear diseases such as chronic suppurative otitis
media or cholesteatoma, presence of other diseases or handicaps, treatment with systemic
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or local antibiotics during the preceding 3 weeks, patients taking topical or systemic
steroids or non-steroidal anti-inflammatory drugs
Interventions Intervention group 1: Antibiotic eardrops; ciprofloxacin (0.3%) otic suspension, 4
drops twice daily for 7 days in the affected ear(s) accompanied by massage of the tragus
Intervention group 2: Saline rinsing; rinsing the ear canal with 2 x 5 ml normal saline
through a syringe by the parents 3 times daily for 7 days
Comparator group:Oral antibiotics; amoxicillin oral suspension, 25 to 50 mg/kg/day
divided into 3 daily doses for 7 days (in case of penicillin allergy, erythromycin, 40 mg/
kg/day divided into 3 doses daily for 7 days was chosen)
Use of additional interventions: at baseline cleansing and suction of the ear canal was
performed in all children. No co-medication was allowed except for mild analgesics
Outcomes Primary outcome: treatment failure at 7 days (defined as presence of ear discharge as
assessed by investigator)
Secondary outcomes: adverse events (otitis externa and tube blockage or extrusion)
Funding sources No funding
Declarations of interest None
Notes Participants lost to follow-up total: 0/68 (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Only in the presence of a nurse in
the clinic, the parents chose a sealed enve-
lope containing a slip of paper describing
the specific treatment. Each envelope was
marked with a random number from a list
of random sequences constructed by the
first author, who was not in contact with
the patients.”
Allocation concealment (selection bias) Low risk Quote: “Only in the presence of a nurse in
the clinic, the parents chose a sealed enve-
lope containing a slip of paper describing
the specific treatment. Each envelope was
marked with a random number from a list
of random sequences constructed by the
first author, who was not in contact with
the patients.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Outcome assessor-blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor-blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised children were included in
analyses
Selective reporting (reporting bias) Unclear risk Protocol was not available; insufficient in-
formation to permit a judgement of low or
high risk
Other bias Unclear risk Baseline characteristics: not balanced for
gender and slight imbalance for age
ITT analysis: performed
Sample size calculations: performed
Use of co-interventions: at baseline cleans-
ing and suction of the ear canal was per-
formed in all children. No co-medication
was allowed except for mild analgesics
NCT01404611
Methods Allocation: randomised
Design: parallel, double-blind
Participants Number: 331 (331 included in analyses)
Age: 6 months to 12 years; mean age 3.2 years (SD 2.4)
Gender: 193 boys (58%), 138 girls (42%)
Setting: unclear, study centres in Europe (Czech Republic, Denmark, Finland, Spain
and Sweden), South Africa, Canada and USA
Eligibility criteria: children aged 6months to 12 years withmoderate or severe, purulent
ear discharge through a grommet of ≤ 3 weeks duration in one or both ears
Exclusion criteria: other ear diseases
Interventions Intervention group 1: antibiotic-corticosteroid eardrops; ciprofloxacin 0.3% plus fluo-
cinolone acetonide 0.025% otic solution twice a day for 7 days in the affected ear(s)
Intervention group 2: antibiotic eardrops; ciprofloxacin 0.3% otic solution twice a day
for 7 days in the affected ear(s)
Comparator group: corticosteroid eardrops; fluocinolone acetonide 0.025% otic solu-
tion twice a day for 7 days in the affected ear(s)
Use of additional interventions: not described
Outcomes Primary outcome: duration of ear discharge (time to cessation of ear discharge)
Secondary outcomes: adverse events
Funding sources This study was sponsored by Laboratorios SALVAT S.A.
Declarations of interest Not described
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Notes Participants lost to follow-up total: 0/331 (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patient was randomized using
IWRS (Interactive Web Response System)
”
Allocation concealment (selection bias) Low risk Double-blind. Quote: “The central labora-
tory was blinded to the treatment assign-
ment of the patient fromwhom the sample
was collected.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Quote: “All study medica-
tion products (test and comparators) had
the same packaging and labels, and the
boxes in which the study medication was
packaged, shipped, and dispensed were
identical in appearance.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised children were included in
the primary analysis
Selective reporting (reporting bias) Low risk Trial was prospectively registered at Clini-
calTrials.gov (NCT01404611) and in the
EUClinical Trials Register (2010-023239-
40). Results were presented for all pre-spec-
ified outcome measures
Other bias Unclear risk Baseline characteristics: balanced
ITT analysis: unclear
Sample size calculations: unclear
Use of co-interventions: not described
Roland 2003
Methods Allocation: randomised
Design: parallel, patient-blinded
Participants Number: 201 (167 included in analyses)
Age: 6 months to 12 years; mean age 2.4 years
Gender: 87 boys (52%), 80 girls (48%)
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Setting: secondary care, 18 clinical centres in the USA
Eligibility criteria: children aged 6 months to 12 years with patent grommets and a
clinical diagnosis of AOM with visible ear discharge of ≤ 3 weeks duration in one or
both ears
Exclusion criteria: fungal or mycobacterial ear infections, active herpes simplex, vac-
cinia, varicella or overt viral infections of the tympanic membrane, mastoiditis or other
suppurative non-infectious ear infections, chronic nasal obstruction or persistent rhinor-
rhoea, a prior or current history of immunosuppressive disorders or immunosuppressive
therapy, acute renal disorders, active hepatitis, diabetes or conditions that may predispose
to neurosensory hearing loss; short-term antibiotics use in prior 2 days and long-term
antibiotics use in prior 7 to 14 days
Interventions Intervention group: antibiotic-corticosteroid eardrops; ciprofloxacin (0.3%)/dexam-
ethasone (0.1%) otic suspension, 3 drops twice daily for 7 days in the affected ear(s)
Comparator group: antibiotic eardrops; ciprofloxacin (0.3%) otic suspension, 3 drops
twice daily for 7 days in the affected ear(s)
Use of additional interventions:
In both treatment groups, the ear canal was cleaned of all fluid and debris via suction
(aural toilet) at baseline
Analgesic use was restricted to paracetamol (acetaminophen)
Any other topical or systemic antimicrobial treatment or anti-inflammatory agents were
not allowed. Any dermatologic, nasal or inhaled corticosteroids (> 800 µg/day) or cor-
ticosteroid-antibiotic combinations were discontinued prior to study entry
Outcomes Primary outcome: time to cessation of ear discharge (parent-reported)
Secondary outcomes: investigator assessment of clinical response (presence or absence
of ear discharge), reduction of granulation tissue, microbiologic response; adverse events,
continued tube patency, audiometric evaluation at baseline and at end of study period
Funding sources This study was supported by a grant from Alcon Research Ltd (Fort Worth, TX)
Declarations of interest None stated
Notes Participants lost to follow-up total:34/201 (17%); insufficient information to calculate
the number of children excluded from the intervention and comparator groups
34 culture-negative children were excluded from analyses; 17/34 were subsequently ex-
cluded due to failure to conform to inclusion/exclusion criteria. The remaining 17 pa-
tients were clinically cured at end of treatment (8 children treated with ciprofloxacin/
dexamethasone, and 9 children treated with ciprofloxacin only)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Quote: “The patients were assigned equally
(1:1) via a randomization code to receive
ototopical treatment with either ciproflo-
xacin 0.3% plus dexamethasone 0.1% otic
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suspension or ciprofloxacin 0.3% oph-
thalmic solution.”
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patient-blinded
Quote: “Both medications were provided
in opaque white plastic dropper bottles [.
..] Because of the physical distinction be-
tween the suspension and solution formu-
lations, the study is best described as pa-
tient-masked (i.e., patients had no knowl-
edge of their treatment assignment) rather
than double-masked. However, all reason-
able efforts weremade tomaintainmasking
of the clinical investigators. The study co-
ordinator, not the clinical investigator, per-
formed the initial dosing and subsequent
dispensing of the medication.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Patient-blinded. Time to cessation of ot-
orrhoea and adverse events were recorded
from parental diaries. Efforts were made to
maintain masking of the clinical investiga-
tors (see above)
Incomplete outcome data (attrition bias)
All outcomes
High risk 34/201 (17%); 34 culture-negative chil-
dren were excluded from analyses
Insufficient information to calculate the
number of children excluded from the in-
tervention and comparator groups
Selective reporting (reporting bias) Unclear risk Protocol was not available; insufficient in-
formation to permit a judgement of low or
high risk
Other bias Unclear risk Baseline characteristics: balanced
ITT analysis: not performed
Sample size calculations: not performed
Use of co-interventions: similar across
groups (aural toilet at baseline)
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Methods Allocation: randomised
Design: parallel, outcome assessor-blinded
Participants Number: 599 (423 included in analyses)
Age: 6 months to 12 years; mean age 2.45 years (SD 2.37 years)
Gender: 373 boys (62%), 226 girls (32%)
Setting: secondary care, 39 clinical centres in the USA and Canada
Eligibility criteria: children aged 6 months to 12 years with patent grommets and a
clinical diagnosis of uncomplicated AOMwith ear discharge (drainage visible to parent/
guardian) of ≤ 3 weeks duration in one or both ears
Exclusion criteria: acute or malignant otitis externa; known or suspected fungal or my-
cobacterial ear infections; history of or active viral infections of the tympanic membrane;
mastoiditis; infections requiring systemic antibiotics; otologic surgery in the previous
year (except that confined to tympanic membrane); patients with diabetes, immuno-
suppressive disorders, acute/chronic renal disease, active hepatitis, chronic nasal obstruc-
tion and/or persistent rhinorrhoea, complicating structural anomalies, known/suspected
quinolone hypersensitivity; menarche (girls); use of topical (otic or ophthalmic) corti-
costeroids or antibiotics concurrently or within the preceding 3 days, systemic corticos-
teroids within the preceding 7 days, inhaled corticosteroids at doses of 800 g/day, topical
antibiotics for skin infections within the preceding 7 days
Interventions Intervention group: antibiotic-corticosteroid eardrops; ciprofloxacin (0.3%)/dexam-
ethasone (0.1%) otic suspension, 4 drops twice daily for 7 days in the affected ear(s)
Comparator group: antibiotic eardrops; ofloxacin (0.3%) otic solution, 5 drops twice
daily for 10 days in the affected ear(s)
Use of additional interventions:
In both treatment groups, the ear canal was cleaned of all fluid and debris via suction
(aural toilet) at baseline. Use of topical otic analgesics/anaesthetics or antiseptic washes,
or non-steroidal anti-inflammatory drugs was not allowed, except for oral paracetamol
(acetaminophen) for relief of pain
Outcomes Primary outcome: at 18 + 3 days: investigator assessment of clinical response (presence
or absence of ear discharge), microbiologic response, treatment failure rate based on the
number of children who were discontinued from the study because they did not respond
to the assigned therapy
Secondary outcomes: time to cessation of ear discharge (parent-reported and as assessed
by the investigator during each study visit, adverse events (parent-reported), audiometric
evaluations
Funding sources This study was supported by a grant from Alcon Research Ltd (Fort Worth, TX)
Declarations of interest Dr Roland is an independent physician who was paid by the sponsor for services as a
medical monitor and consultant.DrsKreisler, Reese, Fornelli and Lanier are independent
physicians who received compensation from the sponsor for study expenses but received
no other financial incentives
Notes Participants lost to follow-up total: 176/599 (29%); 423 children were included in the
modified intention-to-treat analyses (received treatment, met inclusion and exclusion
criteria, had positive culture for bacteria at day 1)
Participants lost to follow-up intervention group: 90/297 (30%)
41Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Roland 2004 (Continued)
Participants lost to follow-up comparator group: 86/302 (28%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Outcome assessor-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor-blinded; those conduct-
ing the clinical observations were unaware
of the treatment assignments. However,
time to cessation of otorrhoea and adverse
events were recorded from parental diaries
Incomplete outcome data (attrition bias)
All outcomes
High risk 176/599 (29%) excluded from analyses;
423 children were included in themodified
intention-to-treat analyses (received treat-
ment, met inclusion and exclusion criteria,
had positive culture for bacteria at day 1)
Selective reporting (reporting bias) Unclear risk Protocol was not available; insufficient in-
formation to permit a judgement of low or
high risk
Other bias Unclear risk Baseline characteristics: balanced
ITT analysis: not performed
Sample size calculations: not performed
Use of co-interventions: similar across
groups (aural toilet at baseline)
Ruohola 1999
Methods Allocation: randomised
Design: parallel, double-blind
Participants Number: 70 (50 included in analyses)
Age: 6 months to 12 years; median age 1.9 years
Gender: 28 boys (56%), 22 girls (44%)
Setting: tertiary care, Department of Pediatrics, Turku and Department of Otorhino-
laryngology, Helsinki, Finland
Eligibility criteria: children aged 6 months to 12 years with ear discharge through a
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grommet of ≤ 48 hours duration in one or both ears
Exclusion criteria: grommet placement or any antimicrobial treatment during the pre-
ceding 2 weeks; ear discharge during the preceding 4 weeks; use of systemic, inhaled or
intranasal corticosteroids; allergy to penicillin or amoxicillin; known immunodeficiency;
Down syndrome, cleft palate, diabetes mellitus, varicella or recent exposure to a patient
with varicella; and middle ear granulomatous tissue or polyp
Interventions Intervention group: oral corticosteroids; oral prednisolone 2 mg/kg/day divided into 3
equal doses for 3 days
Comparator group: placebo for 3 days
Use of additional interventions: all children received co-treatment with amoxicillin-
clavulanate 40 to 10 mg/kg/day divided into 2 doses for 7 days and their ear canals were
cleaned by suction daily. The use of eardrops was not permitted
Outcomes Primary outcome: duration of ear discharge as assessed daily by a study physician and
defined as ceased at the visit when no more discharge could be obtained by suction
Secondary outcomes: adverse events, recurrence of ear discharge
Funding sources This study was supported by grants from the Academy of Finland, the Foundation for
Pediatric Research, Finland and Emil Aaltonen Foundation, Finland. The study drugs
were provided by Leiras Oy and SmithKline Beecham
Declarations of interest None stated
Notes Participants lost to follow-up total: 20/70 (29%) excluded from final analyses. Insuf-
ficient information to calculate the number of children excluded from the intervention
and comparator groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization was done ac-
cording to a computer-based scheme by
Leiras Oy, which also performed the pack-
ing and labeling of the study drugs”
Allocation concealment (selection bias) Low risk Double-blind. Packing and labelling of
prednisolone and placebo was “matched”.
In addition, randomisation was done ac-
cording to a computer-based scheme and
the participants were given the next avail-
able (i.e. the lowest number) bottle of med-
ication
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 20/70 (29%) excluded from final analy-
ses. Insufficient information to calculate
the number of children excluded from the
intervention and comparator groups
Selective reporting (reporting bias) Unclear risk Protocol was not available; insufficient in-
formation to permit a judgement of low or
high risk
Other bias Unclear risk Baseline characteristics: balanced
ITT analysis: not performed
Sample size calculations: performed
Use of co-interventions: similar across
groups (daily suction of ear canal)
Ruohola 2003
Methods Allocation: randomised
Design: parallel, double-blind
Participants Number: 79 (66 excluded from analyses; 79 children included in analyses according to
a worst-case scenario)
Age: 6 months to 6 years; median age 24 months
Gender: 44 boys (67%), 22 girls (33%)
Setting: primary care, Finland
Eligibility criteria: children aged 6 months to 6 years with ear discharge through a
grommet of ≤ 48 hours duration in one or both ears
Exclusion criteria: grommet placement or any antimicrobial treatment during the pre-
ceding 2 weeks; ear discharge during the preceding 4 weeks; use of systemic, inhaled or
intranasal corticosteroids during the preceding 2 weeks; allergy to penicillin or amoxi-
cillin; known immunodeficiency; Down syndrome, cleft palate, diabetes mellitus, gran-
ulation or polyp in the tympanic membrane
Interventions Intervention group: oral antibiotics; amoxicillin-clavulanate 45mg/kg/day divided into
2 doses for 7 days
Comparator group: placebo for 7 days
Use of additional interventions: ear canals were cleaned by suction daily. The use
of eardrops or any other medications was not permitted, except for paracetamol (ac-
etaminophen)
Outcomes Primary outcome: duration of ear discharge as assessed daily by a study physician and
defined as ceased at the visit when no more discharge could be obtained by suction
Secondary outcomes: duration of bacterial growth in middle-ear fluid, adverse events
44Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ruohola 2003 (Continued)
Funding sources This study was supported by the Foundation of Pediatric Research, the Jenny and Antti
Wihuri Foundation, and the Academy of Finland. The study drugs were provided by
SmithKline Beecham Pharmaceuticals, Bristol, TN
Declarations of interest None stated
Notes Participants lost to follow-up total: 13/79 (16%); however, the authors did perform
ITT analyses in which all randomised children were analysed according to the worst-
case scenario (if the actual duration of ear discharge was unknown, it was determined as
8 days)
Participants lost to follow-up intervention group: 5/39 (13%)
Participants lost to follow-up comparator group: 7/40 (18%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The random allocation sequence
was done in blocks of 4 according to a com-
puterized scheme by the Department of
Biostatistics, University of Turku, and the
medication bottles were labeled and pro-
vided for us by the pharmacy of TurkuUni-
versity Hospital.”
Allocation concealment (selection bias) Low risk Double-blind. Quote: “ The randomiza-
tion list included numbers from 1 to 100,
and the study physicians allocated each en-
rolled individual in consecutive order of the
study entry to receive the medication bot-
tles with the text ie, the lowest number in
the list”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. The masking of the study
drugs was ensured by the identical appear-
ance, smell and taste of the syrups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 13/79 (16%) excluded from final analy-
ses; however, the authors did perform ITT
analyses in which all randomised children
were analysed according to the worst-case
scenario (if the actual duration of ear dis-
charge was unknown, it was determined as
8 days)
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Selective reporting (reporting bias) Unclear risk Protocol was not available; insufficient in-
formation to permit a judgement of low or
high risk
Other bias Low risk Baseline characteristics: balanced
ITT analysis: modified ITT analysis per-
formed (worst-case scenario)
Sample size calculations: performed
Use of co-interventions: similar across
groups (daily suction of ear canal)
van Dongen 2014
Methods Allocation: randomised
Design: parallel, open-label
Participants Number: 230 (228 included in analyses)
Age: 1 to 10 years; mean age 4.5 years (SD 2.0 years)
Gender: 133 boys (58%), 97 girls (52%)
Setting: primary and secondary care, the Netherlands
Eligibility criteria: children aged 1 to 10 years with a clinical diagnosis of uncomplicated
ear discharge through a grommet of ≤ 7 days duration in one or both ears
Exclusion criteria: body temperature of more than 38.5 °C, antibiotics during the
previous 2 weeks, grommets placed within the previous 2 weeks, episode of ear discharge
in the previous 4weeks, 3 ormore episodes in the previous 6months or 4 ormore episodes
in the previous year, Down syndrome, craniofacial anomaly, known immunodeficiency,
allergy to the medications used in this study
Interventions Intervention group: antibiotic-corticosteroid eardrops; hydrocortisone-bacitracin-col-
istin otic suspension, 5 drops 3 times daily for 7 days in the affected ear(s)
Intervention group 2: oral antibiotics; amoxicillin/clavulanic acid oral suspension; 30/
7.5 mg/kg per day divided into 3 doses for 7 days
Comparator group: initial observation; initial observation (no assigned medication
prescription to fill) for 2 weeks
Use of additional interventions: parents of children assigned to treatment with antibi-
otic eardrops were instructed to clean the outer ear of any discharge that could easily be
removed with a tissue before applying the drops. After 2 weeks, further management of
ear discharge was left to the discretion of the child’s physician
Outcomes Primary outcome: treatment failure defined as the presence of ear discharge in one or
both ears, as observed otoscopically by the study physician 2 weeks after study group
assignment
Secondary outcomes: duration of the initial ear discharge episode (from study group
assignment up to the first day of ear discharge that was followed by 7 or more days
without ear discharge), total number of days with ear discharge during 6 months of
follow-up, number of recurrent ear discharge episodes (> 1 day with ear discharge after 7
days without ear discharge) during 6 months of follow-up, complications and treatment-
related adverse events in the first 2 weeks, generic and disease-specific health-related
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quality of life at 2 weeks of follow-up
Funding sources This study was supported by a grant fromNetherlandsOrganization for Health Research
and Development
Declarations of interest None declared
Notes Participants lost to follow-up total: 2/230 (1%)
Participants lost to follow-up intervention group: 0/76 (0%)
Participants lost to follow-up intervention group 2: 0/77 (0%)
Participants lost to follow-up comparator group: 2/77 (2%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “An independent data manager
generated a randomization sequence (with
the use of block sizes of six), with stratifica-
tion according to age (<4 years vs > 4 yrs).
”
Allocation concealment (selection bias) Low risk Quote: “The study physician accessed the
trial randomization website at the conclu-
sion of the home visit to obtain the study
group assignment. The randomization as-
signment was concealed and could not be
predicted in advance of or during enroll-
ment.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/230 (1%) children excluded from analy-
ses
Selective reporting (reporting bias) Low risk Trial registered before start of trial; Nether-
lands Trial Register number, NTR1481
Full protocol available on NEJM.org; out-
comes listed at NTR and protocol reported
in paper
Other bias Unclear risk Baseline characteristics: balanced
ITT analysis: performed
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Sample size calculations: performed
Use of co-interventions: parents of chil-
dren assigned to treatment with antibiotic
eardrops were instructed to clean the outer
ear of any discharge that could easily be
removed with a tissue before applying the
drops. After 2 weeks, further management
of ear discharge was left to the discretion of
the child’s physician
AOM: acute otitis media
ENT: ear, nose and throat
ITT: intention-to-treat
SD: standard deviation
TOC: test of cure
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chee 2016 STUDY TYPE
Review article
Dohar 1999 ALLOCATION
Not a randomised trial
Giles 2007 INTERVENTIONS
Treatment to prevent ear discharge after insertion of grommets
Goldblatt 2001 STUDY TYPE
Review article
Granath 2008 PARTICIPANTS
14/50 randomised children (24%) did not have ear discharge during the study period and 2/41 ear discharge
episodes occurred within the first 2 weeks after tube placement
Manolidis 2004 STUDY TYPE
Review article
NCT01908803 INTERVENTIONS
Trial comparing 2 types of antibiotic-corticosteroid eardrops combinations
NCT01994642 INTERVENTIONS
Trial comparing 2 types of antibiotic-corticosteroid eardrops combinations
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Strachan 2000 INTERVENTIONS
Trial comparing 2 types of antibiotic-corticosteroid eardrops combinations
Characteristics of studies awaiting assessment [ordered by study ID]
NCT00578474
Methods Allocation: randomised
Design: parallel, stated to be double-blind
Participants Number: 911
Eligibility criteria: children aged 6 months to 12 years with ear discharge (visible by parent/guardian) through a
grommet of ≤ 12 days duration in one or both ears
Exclusion criteria: silver oxide, silver salt, t-type or long-shafted grommet, ear surgery other than grommets in prior
year, menarche, diabetes mellitus, any disease that would negatively affect the conduct of the study, pre-disposition
to neurosensory hearing loss
Use of additional interventions: analgesics other than paracetamol (acetaminophen), systemic antibiotics are not
allowed during the study
Interventions Intervention group: antibiotic-corticosteroid eardrops; Moxidex otic solution 4 drops twice daily for 7 days in the
affected ear(s)
Comparator group: antibiotic eardrops; ofloxacin otic solution 5 drops twice daily for 10 days in the affected ear(s)
Outcomes Primary outcome: clinical cure rate at the test of cure visit as determined by the investigator
Secondary outcomes: time to cessation of otorrhoea, treatment failures, microbiological outcome
Notes https://clinicaltrials.gov/show/NCT00578474 (accessed 18 April 2016)
Official title: ’Safety and efficacy of a topical otic formulation in the treatment of acute otitis media with otorrhea
through tympanostomy tubes (AOMT)’
Sponsor: Alcon Research
Status: study has been completed, but trial results are not available (study start date:December 2005; study completion
date: August 2008)
NCT00579189
Methods Allocation: randomised
Design: parallel, stated to be double-blind
Participants Number: 776
Eligibility criteria: children aged 6 months to 12 years with ear discharge (visible by parent/guardian) through a
grommet of ≤ 12 days duration in one or both ears
Exclusion criteria: silver oxide, silver salt, t-type or long-shafted grommet, ear surgery other than grommets in prior
year, menarche, diabetes mellitus, any disease that would negatively affect the conduct of the study, pre-disposition
to neurosensory hearing loss
Use of additional interventions: analgesics other than paracetamol (acetaminophen), systemic antibiotics are not
allowed during the study
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Interventions Intervention group: antibiotic-corticosteroid eardrops; Moxidex otic solution 4 drops twice daily for 7 days in the
affected ear(s)
Comparator group: antibiotic eardrops; moxifloxacin otic solution 4 drops twice daily for 7 days in the affected ear
(s)
Outcomes Primary outcome: clinical cure rate at the test of cure visit as determined by the investigator
Secondary outcomes: time to cessation of otorrhoea, treatment failures, microbiological outcome
Notes https://clinicaltrials.gov/show/NCT00579189 (accessed 18 April 2016)
Official title: ’Safety and efficacy of a topical otic formulation in the treatment of acute otitis media with otorrhea
through tympanostomy tubes (AOMT)’
Sponsor: Alcon Research
Status: study has been completed, but trial results are not available (study start date: January 2006; study completion
date: January 2009)
NCT01071902
Methods Allocation: randomised
Design: parallel, double-blind, placebo-controlled
Participants Number: 400
Eligibility criteria: children aged 6 months to 12 years with ear discharge (visible by parent/guardian) through a
grommet of ≤ 12 days duration in one or both ears
Exclusion criteria: children not free from ear discharge for 7 days or less following grommet insertion, grommets
with antimicrobial activity and/or longer than 2.5 mm, ear surgery other than grommets in prior year, menarche,
diabetes mellitus, any disease that would negatively affect the conduct of the study, pre-disposition to neurosensory
hearing loss
Use of additional interventions: analgesics other than paracetamol (acetaminophen), systemic antibiotics are not
allowed during the study
Interventions Intervention group 1: antibiotic-corticosteroid eardrops; Moxidex otic solution 4 drops twice daily for 7 days in the
affected ear(s)
Intervention group 2: antibiotic eardrops; moxifloxacin otic solution 4 drops twice daily for 7 days in the affected
ear(s)
Comparator group: placebo; vehicle 4 drops twice daily for 7 days in the affected ear(s)
Outcomes Primary outcome: clinical cure at end of treatment (day 8)
Secondary outcomes: time to cessation of otorrhoea, microbiological success at end of treatment (day 8)
Notes https://clinicaltrials.gov/show/NCT01071902 (accessed 18 April 2016)
Official title: ’Safety and efficacy evaluation of topical Moxidex otic solution in the treatment of acute otitis media
with otorrhea in tympanostomy tubes’
Sponsor: Alcon Research
Status: study has been terminated (’management decision’, no further details available; study start date: February
2010; study stop date: October 2011)
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of ear discharge at
one week
1 42 Risk Ratio (M-H, Fixed, 95% CI) 2.58 [1.27, 5.22]
2 Adverse events likely to be
related to the use of study
medications
3 705 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.12, 1.09]
3 Resolution of ear discharge at
two to four weeks
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Antibiotic-corticosteroid
eardrops versus oral antibiotics
2 232 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [1.35, 1.88]
3.2 Antibiotic-only eardrops
versus oral antibiotics
1 233 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.91, 1.09]
4 Proportion of patients with
chronic ear discharge
1 148 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.02, 1.67]
5 Proportion of patients with tube
blockage
2 121 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.33, 4.45]
Comparison 2. Sensitivity analysis - Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events likely to be
related to the use of study
medications
1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.51, 1.52]
2 Resolution of ear discharge at
two weeks
1 153 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.38, 2.08]
Comparison 3. Antibiotic eardrops (with or without a corticosteroid) versus saline rinsing of the ear canal
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of ear discharge at
one week
1 48 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [1.04, 2.69]
2 Proportion of patients with tube
blockage
1 48 Risk Ratio (M-H, Fixed, 95% CI) 1.77 [0.32, 9.67]
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Comparison 4. Antibiotic eardrops (with or without a corticosteroid) versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of ear discharge at
two weeks
1 151 Risk Ratio (M-H, Fixed, 95% CI) 2.09 [1.62, 2.69]
2 Proportion of patients with
chronic ear discharge
1 147 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.62]
Comparison 5. Antibiotic(s)-corticosteroid eardrops versus antibiotic eardrops
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of ear discharge at
less than two weeks
2 590 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [1.33, 2.31]
2 Adverse events likely to be
related to the use of study
medications
3 1023 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.55, 1.32]
3 Resolution of ear discharge at
two to four weeks
2 590 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.90, 1.31]
Comparison 6. Sensitivity analysis - Antibiotic(s)-corticosteroid eardrops versus antibiotic eardrops
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events likely to be
related to the use of study
medications
1 223 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.17]
Comparison 7. Oral antibiotics versus saline rinsing of the ear canal
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of ear discharge at
one week
1 46 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.30, 1.43]
2 Proportion of patients with tube
blockage
1 46 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [0.36, 10.58]
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Comparison 8. Oral antibiotics versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of ear discharge
within two weeks
1 79 Risk Ratio (M-H, Fixed, 95% CI) 2.21 [1.36, 3.60]
2 Adverse events likely to be
related to the use of study
medications
1 79 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.69, 4.25]
3 Resolution of ear discharge at
two weeks
1 152 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.90, 1.69]
4 Proportion of patients with
chronic ear discharge
1 147 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.15, 1.11]
5 Proportion of patients with tube
extrusion
1 79 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.43]
Comparison 9. Oral corticosteroids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of ear discharge
within two weeks
1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.92, 1.26]
2 Adverse events likely to be
related to the use of study
medications
1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.01, 4.63]
Analysis 1.1. Comparison 1 Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics,
Outcome 1 Resolution of ear discharge at one week.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 1 Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics
Outcome: 1 Resolution of ear discharge at one week
Study or subgroup Antibiotic eardrops Oral antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heslop 2010 17/22 6/20 100.0 % 2.58 [ 1.27, 5.22 ]
Total (95% CI) 22 20 100.0 % 2.58 [ 1.27, 5.22 ]
Total events: 17 (Antibiotic eardrops), 6 (Oral antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0087)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours oral antibiotics Favours antibiotic eardrops
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Analysis 1.2. Comparison 1 Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics,
Outcome 2 Adverse events likely to be related to the use of study medications.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 1 Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics
Outcome: 2 Adverse events likely to be related to the use of study medications
Study or subgroup Antibiotic eardrops Oral antibiotics Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dohar 2006 5/39 17/40 30.4 % 0.30 [ 0.12, 0.74 ]
Goldblatt 1998 13/228 77/246 34.7 % 0.18 [ 0.10, 0.32 ]
van Dongen 2014 18/75 21/77 34.9 % 0.88 [ 0.51, 1.52 ]
Total (95% CI) 342 363 100.0 % 0.37 [ 0.12, 1.09 ]
Total events: 36 (Antibiotic eardrops), 115 (Oral antibiotics)
Heterogeneity: Tau2 = 0.80; Chi2 = 16.90, df = 2 (P = 0.00021); I2 =88%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours antibiotic eardrops Favours oral antibiotics
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Analysis 1.3. Comparison 1 Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics,
Outcome 3 Resolution of ear discharge at two to four weeks.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 1 Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics
Outcome: 3 Resolution of ear discharge at two to four weeks
Study or subgroup Antibiotic eardrops Oral antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotic-corticosteroid eardrops versus oral antibiotics
Dohar 2006 33/39 24/40 35.7 % 1.41 [ 1.06, 1.88 ]
van Dongen 2014 72/76 43/77 64.3 % 1.70 [ 1.38, 2.08 ]
Subtotal (95% CI) 115 117 100.0 % 1.59 [ 1.35, 1.88 ]
Total events: 105 (Antibiotic eardrops), 67 (Oral antibiotics)
Heterogeneity: Chi2 = 1.06, df = 1 (P = 0.30); I2 =5%
Test for overall effect: Z = 5.48 (P < 0.00001)
2 Antibiotic-only eardrops versus oral antibiotics
Goldblatt 1998 107/120 101/113 100.0 % 1.00 [ 0.91, 1.09 ]
Subtotal (95% CI) 120 113 100.0 % 1.00 [ 0.91, 1.09 ]
Total events: 107 (Antibiotic eardrops), 101 (Oral antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 23.62, df = 1 (P = 0.00), I2 =96%
0.1 0.2 0.5 1 2 5 10
Favours oral antibiotics Favours antibiotic eardrops
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Analysis 1.4. Comparison 1 Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics,
Outcome 4 Proportion of patients with chronic ear discharge.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 1 Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics
Outcome: 4 Proportion of patients with chronic ear discharge
Study or subgroup Ab-corti eardrops Oral antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
van Dongen 2014 1/74 5/74 100.0 % 0.20 [ 0.02, 1.67 ]
Total (95% CI) 74 74 100.0 % 0.20 [ 0.02, 1.67 ]
Total events: 1 (Ab-corti eardrops), 5 (Oral antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours ab-corti eardrops Favours oral antibiotics
Analysis 1.5. Comparison 1 Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics,
Outcome 5 Proportion of patients with tube blockage.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 1 Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics
Outcome: 5 Proportion of patients with tube blockage
Study or subgroup Antibiotic eardrops Oral antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dohar 2006 1/39 0/40 13.6 % 3.08 [ 0.13, 73.27 ]
Heslop 2010 3/22 3/20 86.4 % 0.91 [ 0.21, 4.00 ]
Total (95% CI) 61 60 100.0 % 1.20 [ 0.33, 4.45 ]
Total events: 4 (Antibiotic eardrops), 3 (Oral antibiotics)
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours antibiotic eardrops Favours oral antibiotics
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Analysis 2.1. Comparison 2 Sensitivity analysis - Antibiotic eardrops (with or without a corticosteroid)
versus oral antibiotics, Outcome 1 Adverse events likely to be related to the use of study medications.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 2 Sensitivity analysis - Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics
Outcome: 1 Adverse events likely to be related to the use of study medications
Study or subgroup Ab-corti eardrops Oral antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
van Dongen 2014 18/75 21/77 100.0 % 0.88 [ 0.51, 1.52 ]
Total (95% CI) 75 77 100.0 % 0.88 [ 0.51, 1.52 ]
Total events: 18 (Ab-corti eardrops), 21 (Oral antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours ab-corti eardrops Favours oral antibiotics
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Analysis 2.2. Comparison 2 Sensitivity analysis - Antibiotic eardrops (with or without a corticosteroid)
versus oral antibiotics, Outcome 2 Resolution of ear discharge at two weeks.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 2 Sensitivity analysis - Antibiotic eardrops (with or without a corticosteroid) versus oral antibiotics
Outcome: 2 Resolution of ear discharge at two weeks
Study or subgroup Ab-corti eardrops Oral antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
van Dongen 2014 72/76 43/77 100.0 % 1.70 [ 1.38, 2.08 ]
Total (95% CI) 76 77 100.0 % 1.70 [ 1.38, 2.08 ]
Total events: 72 (Ab-corti eardrops), 43 (Oral antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 5.04 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours oral antibiotics Favours ab-corti eardrops
Analysis 3.1. Comparison 3 Antibiotic eardrops (with or without a corticosteroid) versus saline rinsing of
the ear canal, Outcome 1 Resolution of ear discharge at one week.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 3 Antibiotic eardrops (with or without a corticosteroid) versus saline rinsing of the ear canal
Outcome: 1 Resolution of ear discharge at one week
Study or subgroup Antibiotic eardrops Saline rinsing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heslop 2010 17/22 12/26 100.0 % 1.67 [ 1.04, 2.69 ]
Total (95% CI) 22 26 100.0 % 1.67 [ 1.04, 2.69 ]
Total events: 17 (Antibiotic eardrops), 12 (Saline rinsing)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.033)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours saline rinsing Favours antibiotic eardrops
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Analysis 3.2. Comparison 3 Antibiotic eardrops (with or without a corticosteroid) versus saline rinsing of
the ear canal, Outcome 2 Proportion of patients with tube blockage.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 3 Antibiotic eardrops (with or without a corticosteroid) versus saline rinsing of the ear canal
Outcome: 2 Proportion of patients with tube blockage
Study or subgroup Ab eardrops Saline rinsing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heslop 2010 3/22 2/26 100.0 % 1.77 [ 0.32, 9.67 ]
Total (95% CI) 22 26 100.0 % 1.77 [ 0.32, 9.67 ]
Total events: 3 (Ab eardrops), 2 (Saline rinsing)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours ab eardrops Favours saline rinsing
Analysis 4.1. Comparison 4 Antibiotic eardrops (with or without a corticosteroid) versus no treatment,
Outcome 1 Resolution of ear discharge at two weeks.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 4 Antibiotic eardrops (with or without a corticosteroid) versus no treatment
Outcome: 1 Resolution of ear discharge at two weeks
Study or subgroup Ab-corti eardrops No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
van Dongen 2014 72/76 34/75 100.0 % 2.09 [ 1.62, 2.69 ]
Total (95% CI) 76 75 100.0 % 2.09 [ 1.62, 2.69 ]
Total events: 72 (Ab-corti eardrops), 34 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 5.68 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours no treatment Favours ab-corti eardrops
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Analysis 4.2. Comparison 4 Antibiotic eardrops (with or without a corticosteroid) versus no treatment,
Outcome 2 Proportion of patients with chronic ear discharge.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 4 Antibiotic eardrops (with or without a corticosteroid) versus no treatment
Outcome: 2 Proportion of patients with chronic ear discharge
Study or subgroup Ab-corti eardrops No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
van Dongen 2014 1/74 12/73 100.0 % 0.08 [ 0.01, 0.62 ]
Total (95% CI) 74 73 100.0 % 0.08 [ 0.01, 0.62 ]
Total events: 1 (Ab-corti eardrops), 12 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours ab-corti eardrops Favours no treatment
Analysis 5.1. Comparison 5 Antibiotic(s)-corticosteroid eardrops versus antibiotic eardrops, Outcome 1
Resolution of ear discharge at less than two weeks.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 5 Antibiotic(s)-corticosteroid eardrops versus antibiotic eardrops
Outcome: 1 Resolution of ear discharge at less than two weeks
Study or subgroup Ab-corti eardrops Antibiotic eardrops Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Roland 2003 40/87 21/80 37.0 % 1.75 [ 1.14, 2.70 ]
Roland 2004 64/207 38/216 63.0 % 1.76 [ 1.23, 2.50 ]
Total (95% CI) 294 296 100.0 % 1.76 [ 1.33, 2.31 ]
Total events: 104 (Ab-corti eardrops), 59 (Antibiotic eardrops)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 4.02 (P = 0.000057)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours antibiotic eardrops Favours ab-corti eardrops
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Analysis 5.2. Comparison 5 Antibiotic(s)-corticosteroid eardrops versus antibiotic eardrops, Outcome 2
Adverse events likely to be related to the use of study medications.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 5 Antibiotic(s)-corticosteroid eardrops versus antibiotic eardrops
Outcome: 2 Adverse events likely to be related to the use of study medications
Study or subgroup Ab-corti eardrops Antibiotic eardrops Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
NCT01404611 0/111 1/112 3.7 % 0.34 [ 0.01, 8.17 ]
Roland 2003 7/103 7/98 17.8 % 0.95 [ 0.35, 2.61 ]
Roland 2004 27/297 32/302 78.5 % 0.86 [ 0.53, 1.40 ]
Total (95% CI) 511 512 100.0 % 0.86 [ 0.55, 1.32 ]
Total events: 34 (Ab-corti eardrops), 40 (Antibiotic eardrops)
Heterogeneity: Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ab-corti eardrops Favours antibiotic eardrops
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Analysis 5.3. Comparison 5 Antibiotic(s)-corticosteroid eardrops versus antibiotic eardrops, Outcome 3
Resolution of ear discharge at two to four weeks.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 5 Antibiotic(s)-corticosteroid eardrops versus antibiotic eardrops
Outcome: 3 Resolution of ear discharge at two to four weeks
Study or subgroup Ab-corti eardrops Antibiotic eardrops Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Roland 2003 78/87 72/80 50.2 % 1.00 [ 0.90, 1.10 ]
Roland 2004 174/207 153/216 49.8 % 1.19 [ 1.07, 1.32 ]
Total (95% CI) 294 296 100.0 % 1.09 [ 0.90, 1.31 ]
Total events: 252 (Ab-corti eardrops), 225 (Antibiotic eardrops)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.37, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours antibiotic eardrops Favours ab-corti eardrops
Analysis 6.1. Comparison 6 Sensitivity analysis - Antibiotic(s)-corticosteroid eardrops versus antibiotic
eardrops, Outcome 1 Adverse events likely to be related to the use of study medications.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 6 Sensitivity analysis - Antibiotic(s)-corticosteroid eardrops versus antibiotic eardrops
Outcome: 1 Adverse events likely to be related to the use of study medications
Study or subgroup Ab-corti eardrops Antibiotic eardrops Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
NCT01404611 0/111 1/112 100.0 % 0.34 [ 0.01, 8.17 ]
Total (95% CI) 111 112 100.0 % 0.34 [ 0.01, 8.17 ]
Total events: 0 (Ab-corti eardrops), 1 (Antibiotic eardrops)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Favours ab-corti eardrops Favours antibiotic eardrops
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Analysis 7.1. Comparison 7 Oral antibiotics versus saline rinsing of the ear canal, Outcome 1 Resolution of
ear discharge at one week.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 7 Oral antibiotics versus saline rinsing of the ear canal
Outcome: 1 Resolution of ear discharge at one week
Study or subgroup Oral antibiotics Saline rinsing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heslop 2010 6/20 12/26 100.0 % 0.65 [ 0.30, 1.43 ]
Total (95% CI) 20 26 100.0 % 0.65 [ 0.30, 1.43 ]
Total events: 6 (Oral antibiotics), 12 (Saline rinsing)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Oral antibiotics versus saline rinsing of the ear canal, Outcome 2 Proportion of
patients with tube blockage.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 7 Oral antibiotics versus saline rinsing of the ear canal
Outcome: 2 Proportion of patients with tube blockage
Study or subgroup Oral antibiotics Saline rinsing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heslop 2010 3/20 2/26 100.0 % 1.95 [ 0.36, 10.58 ]
Total (95% CI) 20 26 100.0 % 1.95 [ 0.36, 10.58 ]
Total events: 3 (Oral antibiotics), 2 (Saline rinsing)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours oral antibiotics Favours saline rinsing
Analysis 8.1. Comparison 8 Oral antibiotics versus placebo or no treatment, Outcome 1 Resolution of ear
discharge within two weeks.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 8 Oral antibiotics versus placebo or no treatment
Outcome: 1 Resolution of ear discharge within two weeks
Study or subgroup Oral antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ruohola 2003 28/39 13/40 100.0 % 2.21 [ 1.36, 3.60 ]
Total (95% CI) 39 40 100.0 % 2.21 [ 1.36, 3.60 ]
Total events: 28 (Oral antibiotics), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours oral antibiotics
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Analysis 8.2. Comparison 8 Oral antibiotics versus placebo or no treatment, Outcome 2 Adverse events
likely to be related to the use of study medications.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 8 Oral antibiotics versus placebo or no treatment
Outcome: 2 Adverse events likely to be related to the use of study medications
Study or subgroup Oral antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ruohola 2003 10/39 6/40 100.0 % 1.71 [ 0.69, 4.25 ]
Total (95% CI) 39 40 100.0 % 1.71 [ 0.69, 4.25 ]
Total events: 10 (Oral antibiotics), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours oral antibiotics Favours placebo
Analysis 8.3. Comparison 8 Oral antibiotics versus placebo or no treatment, Outcome 3 Resolution of ear
discharge at two weeks.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 8 Oral antibiotics versus placebo or no treatment
Outcome: 3 Resolution of ear discharge at two weeks
Study or subgroup Oral antibiotics No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
van Dongen 2014 43/77 34/75 100.0 % 1.23 [ 0.90, 1.69 ]
Total (95% CI) 77 75 100.0 % 1.23 [ 0.90, 1.69 ]
Total events: 43 (Oral antibiotics), 34 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours no treatment Favours oral antibiotics
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Analysis 8.4. Comparison 8 Oral antibiotics versus placebo or no treatment, Outcome 4 Proportion of
patients with chronic ear discharge.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 8 Oral antibiotics versus placebo or no treatment
Outcome: 4 Proportion of patients with chronic ear discharge
Study or subgroup Oral antibiotics No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
van Dongen 2014 5/74 12/73 100.0 % 0.41 [ 0.15, 1.11 ]
Total (95% CI) 74 73 100.0 % 0.41 [ 0.15, 1.11 ]
Total events: 5 (Oral antibiotics), 12 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours oral antibiotics Favours no treatment
Analysis 8.5. Comparison 8 Oral antibiotics versus placebo or no treatment, Outcome 5 Proportion of
patients with tube extrusion.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 8 Oral antibiotics versus placebo or no treatment
Outcome: 5 Proportion of patients with tube extrusion
Study or subgroup Oral antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ruohola 2003 1/39 2/40 100.0 % 0.51 [ 0.05, 5.43 ]
Total (95% CI) 39 40 100.0 % 0.51 [ 0.05, 5.43 ]
Total events: 1 (Oral antibiotics), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours oral antibiotics Favours placebo
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Analysis 9.1. Comparison 9 Oral corticosteroids versus placebo, Outcome 1 Resolution of ear discharge
within two weeks.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 9 Oral corticosteroids versus placebo
Outcome: 1 Resolution of ear discharge within two weeks
Study or subgroup Oral cortico Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ruohola 1999 22/23 24/27 100.0 % 1.08 [ 0.92, 1.26 ]
Total (95% CI) 23 27 100.0 % 1.08 [ 0.92, 1.26 ]
Total events: 22 (Oral cortico), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours oral cortico
Analysis 9.2. Comparison 9 Oral corticosteroids versus placebo, Outcome 2 Adverse events likely to be
related to the use of study medications.
Review: Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube) insertion
Comparison: 9 Oral corticosteroids versus placebo
Outcome: 2 Adverse events likely to be related to the use of study medications
Study or subgroup Oral cortico Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ruohola 1999 0/23 2/27 100.0 % 0.23 [ 0.01, 4.63 ]
Total (95% CI) 23 27 100.0 % 0.23 [ 0.01, 4.63 ]
Total events: 0 (Oral cortico), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours oral cortico
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A D D I T I O N A L T A B L E S
Table 1. Interventions and comparison pairs included in this review
Study ID Antibiotic-
corticos-
teroid
eardrops
Antibiotic-
only
eardrops
Corticos-
teroid-only
eardrops
Oral
antibiotics
Oral
corticos-
teroids
Saline
rinsing
Placebo No treatment
Dohar 2006 x x
Goldblatt
1998
x x
Heslop
2010
x x x
NCT01404611
x x x
Roland
2003
x x
Roland
2004
x x
Ruohola
1999
x x
Ruohola
2003
x x
van Dongen
2014
x x x
Comparison pairs for this review
# Interven-
tion
Compara-
tor
Number of
trials
Study ID
1 Antibiotic
eardrops
(with or
without cor-
ticosteroids)
Oral antibi-
otics
4 Dohar 2006; Goldblatt 1998; Heslop 2010; van Dongen 2014
2 Antibiotic
eardrops
(with or
without cor-
ticosteroids)
Corticos-
teroid-only
eardrops
1 NCT01404611
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Table 1. Interventions and comparison pairs included in this review (Continued)
3 Antibiotic
eardrops
(with or
without cor-
ticosteroids)
Saline rins-
ing
1 Heslop 2010
4 Antibiotic
eardrops
(with or
without cor-
ticosteroids)
Placebo
or no treat-
ment
1 van Dongen 2014
Note: 1 trial terminated, no results available (NCT01071902)
5 Antibiotic-
corticos-
teroid
eardrops
Antibiotic-
only
eardrops
3 NCT01404611; Roland 2003; Roland 2004
Note: 2 completed trials without results (NCT00578474;
NCT00579189) and 1 trial terminated (NCT01071902)
6 Oral antibi-
otics
Saline rins-
ing
1 Heslop 2010
7 Oral antibi-
otics
Placebo
or no treat-
ment
2 Ruohola 2003; van Dongen 2014
8 Oral corti-
costeroids
Placebo 1 Ruohola 1999
Table 2. Overview of the outcomes reported in the included studies
Outcome Dohar
2006
Goldblatt
1998
Heslop
2010
NCT01404611
Roland
2003
Roland
2004
Ruohola
1999
Ruohola
2003
van
Dongen
2014
Primary outcomes
Proportion
of children
with reso-
lution
of ear dis-
charge at <
2 weeks
x x x x x
Adverse
events
likely to be
re-
lated to the
x x x x x x x x
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Table 2. Overview of the outcomes reported in the included studies (Continued)
studymed-
ications
Se-
rious com-
plications
related to
middle ear
infection
x x x x x
Secondary outcomes
Proportion
of children
with reso-
lution
of ear dis-
charge at
2 to 4 weeks x x x x x
4 to 12
weeks
Proportion
of children
without
ear pain
and fever
Dura-
tion of ear
discharge
x x x x x x x
Proportion
of children
with
chronic ear
discharge
(duration
< 4 weeks)
x
Number of
re-
current ear
discharge
episodes
during fol-
low-up
x x
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Table 2. Overview of the outcomes reported in the included studies (Continued)
Proportion
of children
with tube
extrusion
x
Proportion
of children
with tube
blockage
x x x x
Health-re-
lated qual-
ity of life
x
Hearing
levels (au-
diometry)
x x x x
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL MEDLINE (Ovid) EMBASE (Ovid) Web of Science (Web of
Knowledge)
#1 MeSH descriptor: [Mid-
dle Ear Ventilation] explode all
trees
#2 grommet* or tubulation
#3 middle next ear near venti-
lat*
#4 (ventilat* near tube*) and (
(otitis near media) or OME or
ear)
#5 (tympanostomy or middle
next ear or tympanic) near
tube*
#6 ear* near insert* near tube*
#7 #1 or #2 or #3 or #4 or #5
or #6
#8 MeSH descriptor: [Cere-
1 exp Middle Ear Ventilation/
2 (grommet* or tubulation).ab,
ti.
3 (middle adj5 ear adj5 venti-
lat*).ab,ti.
4 ((ventilat* adj5 tube*) and (
(otitis adj5 media) or OME or
ear)).ab,ti
5 ((((tympanostomy or mid-
dle) adj5 ear) or tympanic) adj5
tube*).ab,ti
6 (ear* adj5 insert* adj5 tube*)
.ab,ti.
7 1 or 2 or 3 or 4 or 5 or 6
8 exp Cerebrospinal Fluid Ot-
orrhea/
1 exp Middle Ear Ventilation/
2 (grommet* or tubulation).ab,
ti.
3 (middle adj5 ear adj5 venti-
lat*).ab,ti.
4 ((ventilat* adj5 tube*) and (
(otitis adj5 media) or OME or
ear)).ab,ti
5 ((((tympanostomy or mid-
dle) adj5 ear) or tympanic) adj5
tube*).ab,ti
6 (ear* adj5 insert* adj5 tube*)
.ab,ti.
7 1 or 2 or 3 or 4 or 5 or 6
8 exp Cerebrospinal Fluid Ot-
orrhea/
#1 TOPIC: (grommet* or
tubulation)
#2 TOPIC: (middle near/5 ear
near/5 ventilat*)
#3TOPIC: ((tympanostomy or
(middle near/5 ear) or tym-
panic) near/5 tube*)
#4 TOPIC: (ear* near/5 insert*
near/5 tube*)
#5 TOPIC: ((ventilat* near/5
tube*) and ((otitis near/5 me-
dia) or OME or ear))
#6 #5 OR #4 OR #3 OR #2
OR #1
#7
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(Continued)
brospinal Fluid Otorrhea] ex-
plode all trees
#9 liquorrh* or liquorh* or
otoliquorrh* or otoliquorh*
#10 suppurat* or pus or pu-
rulen* or discharg* or mucosal
or otorrh* or otorh* or Mu-
copurulen* or wet or moist or
weep*
#11 infect* or obstruct*
#12 (acute near otitis near me-
dia) or AOM or AOMT
#13 #8 or #9 or #10 or #11 or
#12
#14 #7 and #13
#15 MeSH descriptor: [Mid-
dle Ear Ventilation] explode all
trees and with qualifier(s): [Ad-
verse effects - AE]
#16 #14 or #15
9 (liquorrh* or liquorh* or
otoliquorrh* or otoliquorh*).
ab,ti
10 (suppurat* or pus or pu-
rulen* or discharg* or mucosal
or otorrh* or otorh* or Mu-
copurulen* or wet or moist or
weep*).ab,ti
11 (infect* or obstruct*).ab,ti.
12 ((acute adj5 otitis adj5 me-
dia) or AOM or AOMT).ab,ti.
13 8 or 9 or 10 or 11 or 12
14 7 and 13
15 exp Middle Ear Ventilation/
ae [Adverse Effects]
16 14 or 15
9 (liquorrh* or liquorh* or
otoliquorrh* or otoliquorh*).
ab,ti
10 (suppurat* or pus or pu-
rulen* or discharg* or mucosal
or otorrh* or otorh* or Mu-
copurulen* or wet or moist or
weep*).ab,ti
11 (infect* or obstruct*).ab,ti.
12 ((acute adj5 otitis adj5 me-
dia) or AOM or AOMT).ab,ti.
13 8 or 9 or 10 or 11 or 12
14 7 and 13
15 exp Middle Ear Ventilation/
ae [Adverse Effects]
16 14 or 15
TOPIC: (liquorrh* or liquorh*
or otoliquorrh* or otoliquorh*)
#8 TOPIC: (suppurat* or pus
or purulen* or discharg* or mu-
cosal or otorrh* or otorh* or
Mucopurulen* or wet or moist
or weep*)
#9 TOPIC: (infect* or ob-
struct*)
#10 TOPIC: ((acute near/5 oti-
tis near/5 media) or AOM or
AOMT)
#11 #10 OR #9 OR #8 OR #7
#12 #11 AND #6
#13
CINAHL (EBSCO) ICTRP ClinicalTrials.gov LILACS
S16 S14 OR S15
S15 (MH “Middle Ear Ventila-
tion/AE”)
S14 S7 AND S13
S13 S8OR S9ORS10ORS11
OR S12
S12TX (acuteN5otitisN5me-
dia) or AOM or AOMT
S11 TX infect* or obstruct*
S10 TX suppurat* or pus or pu-
rulen* or discharg* or mucosal
or otorrh* or otorh* or Mu-
copurulen* or wet or moist or
weep*
S9 TX liquorrh* or liquorh* or
otoliquorrh* or otoliquorh*
S8 (MH “Cerebrospinal Fluid
Otorrhea”)
S7 S1ORS2ORS3ORS4OR
S5 OR S6
S6 middle N5 ear N5 ventilat*
S5TX ear*N5 insert*N5 tube*
S4 TX (tympanostomy or mid-
dle N5 ear or tympanic) N5
tube*
S3 TX (ventilat* N5 tube*) and
grommet*ORmiddleANDear
AND venitalat* OR tubulation
OR tympanostomy AND tube
grommet* OR (middle
AND ear AND venitalat*) OR
tubulation OR (tympanostomy
AND tube)
(TW:grommet$ OR TW:tubu-
lation OR (TW:Middle AND
TW:Ear AND TW:Ventilat$)
OR (TW:ventilac$ AND (TW:
Oído OR TW:Orelha) AND
TW:medi$) OR (TW:tympa-
nostomy AND TW:tube))
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(Continued)
((otitis N5 media) or OME or
ear)
S2 TX grommet* or tubulation
S1 (MH “Middle Ear Ventila-
tion”)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review has been based on a published protocol (Javed 2015). Any differences between the protocol and the review can be found
below.
Title
The title has been changed from ’Pharmacological and conservative interventions for ear discharge associatedwith grommets (ventilation
tubes) outside the postoperative period’ to ’Interventions for children with ear discharge occurring at least two weeks following grommet
(ventilation tube) insertion’.
Participants
In our review we focused on children only, whereas we stated in the protocol that we would include “patients of any age”. Although
we did not limit our search strategy to children only, we found no relevant trials focusing on adults. Recognising that the vast majority
of patients with grommets who develop ear discharge encountered in clinical practice are children and to reflect the findings of the
included studies, we decided to limit our review to children only.
Outcomes
In the protocol, we listed “Proportion of patients with resolution of ear discharge at various time points (up to two weeks, two to four
weeks and four to 12 weeks)” as a primary outcome. In this review, we included “Proportion of children with resolution of ear discharge
at short-term follow-up (< two weeks)” as a primary outcome and listed “Proportion of children with resolution of ear discharge at
intermediate- (two to four weeks) and long-term (four to 12 weeks) follow-up” as important secondary outcomes.
N O T E S
This review replaces ’Interventions for ear discharge associated with grommets (ventilation tubes)’ (Vaile 2006), which is now out of
date.
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